TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 1 of 65  
CONFIDENTIALITY STATEMENT 
The information contained in this document is a confidential communication.  Acceptance of this 
document constitutes an agreement by the recipien t(s) that no unpublished information contained 
herein will be published or disclosed without the sponsor’s prior written approval, except that 
this document may be disclosed to appropriate Institutional Review Bo ards/Ethics Committees 
under condition that they are also requ ested to maintain  confidentiality. 
    
A Pivotal Clinical Study to Evaluate the Safety and 
Effectiveness of the  
Ovation™ Abdominal Stent Graft System 
 
 
 
 
Protocol Number 771-0006 
 
   
 
    Revision:   J (July 7, 2011) 
  Sponsor Name:   TriVascular, Inc. 
 Address:    3910 Brickway Blvd. 
   Santa Rosa, CA 95403        
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 3 of 65 Protocol Signature Page 
 
  
A Pivotal Clinical Study to Evaluate the Safety and Effectiveness 
of the Ovation™ Abdominal Stent Graft System 
Protocol Number 771-0006 
  
Revision:   J 
 Sponsor Name:  TriVascular, Inc. 
Address:   3910 Brickway Blvd. 
   Santa Rosa, CA 95403  I have read this protocol, including all appendi ces, and I agree that it contains all necessary 
details for me and my staff to conduct this study as described.  I will personally oversee the conduct of the study as outlined herein, in a ccordance with FDA regulations 21 CFR 812, Good 
Clinical Practice (GCP) and the Declaration of Helsinki.  I will provide all study personnel under my supervision with access to this document and all pertinent information provided by TriVascular, Inc.  I will discuss this material with them to 
ensure that they are fully informed regarding th e investigational device, the safety and efficacy 
parameters, and the conduct of the study in gene ral.  I understand that I am responsible for 
providing adequate supervision of those to whom protocol-related tasks ar e delegated and that I 
am accountable for regulatory violations from fail ure to adequately superv ise the conduct of the 
clinical study. I agree to provide all subjects with inform ed consent forms, as required by 
government and ICH regulations.  I agree to repor t to TriVascular any adverse experiences in 
accordance with the terms of this protocol. Fu rthermore, I am aware that, prior to the 
commencement of this study, the Institutional Revi ew Board responsible for such matters must 
approve this protocol for the clinical  facility where it will be conducted. 
  Site Principal Investigator:                 
Investigator Name (Printed)    Signature         
Date 
 
 
 
     
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 4 of 65  
   
TABLE OF CONTENTS 
TABLE OF CO NTENTS ............................................................................................................. ............................... 4  
PROTOCOL SUMMARY .............................................................................................................. ............................ 6  
1.0 STUDY GOAL .................................................................................................................... ........................... 9  
2.0 BACKGROUND AND RATIONALE ...................................................................................................... . 10 
2.1 CONVENTIONAL TREATMENT OF ABDOMINAL AORTIC ANEURYSM  .......................................................... 10  
3.0 INDICATIONS ................................................................................................................... ......................... 14  
4.0 DEVICE DESCRIPTION ........................................................................................................................... 15  
5.0 STUDY DESIGN .................................................................................................................. ....................... 18  
5.1 ELIGIBILITY CRITERIA  ............................................................................................................................... 18  
5.2 STUDY POPULATION  .................................................................................................................................. 19  
5.3 WITHDRAWAL AND LOST-TO-FOLLOW -UP ................................................................................................ 19  
5.4 DURATION OF STUDY  ................................................................................................................................ 20  
6.0 STUDY PROCEDURES .............................................................................................................. ............... 21  
6.1 PATIENT SCREENING  ................................................................................................................................. 21  
6.2 PRE-PROCEDURE EVALUATION  .................................................................................................................. 21  
6.3 TREATMENT PERIOD (IMPLANT /SURGICAL PROCEDURE ) ............................................................................ 21  
6.4 PRE-DISCHARGE  ........................................................................................................................................ 22  
6.5 POST-TREATMENT FOLLOW -UP PERIOD  ..................................................................................................... 22  
6.6 UNSCHEDULED FOLLOW -UP VISITS  ........................................................................................................... 23  
6.7 ANNUAL FOLLOW -UP VISITS  ...................................................................................................................... 23  
6.8 DISCONTINUATION FROM STUDY  ............................................................................................................... 23  
7.0 STUDY OBJE CTIVES .............................................................................................................. ................. 24  
7.1 PRIMARY OBJECTIVES  ............................................................................................................................... 24  
8.0 DEFINITIONS ............................................................................................................................................ 25  
8.1 ENDOLEAK  ................................................................................................................................................ 25  
8.2 MIGRATION  ............................................................................................................................................... 25  
8.3 PATENCY  ................................................................................................................................................... 25  
8.4 LOSS OF STENT GRAFT INTEGRITY  ............................................................................................................ 25  
8.5 AAA  ENLARGEMENT  ................................................................................................................................ 25  
8.6 SURGICAL CONVERSION  ............................................................................................................................ 2 5 
8.7 IMAGING CORE LAB .................................................................................................................................. 25  
8.8 EXPLANT EVALUATION  ............................................................................................................................. 26 
8.9 ADVERSE EVENTS  ..................................................................................................................................... 26  
8.10 SERIOUS ADVERSE EVENTS (SAE) ............................................................................................................ 27  
8.11 MAJOR ADVERSE EVENTS (MAE) ............................................................................................................. 28  
8.12 UNANTICIPATED ADVERSE DEVICE EFFECT (UADE) ................................................................................ 28  
8.13 CONVERSION TO OPEN SURGICAL REPAIR  ................................................................................................. 28  
8.14   TECHNICAL FAILURES  ............................................................................................................................... 29  
8.15 DEATHS  ..................................................................................................................................................... 29  
8.16 EXPLANTS  ................................................................................................................................................. 29  
9.0  ENDPOINTS AND TECHNIQUES FOR MEASUREMENT ................................................................ 30  
9.1 PRIMARY ENDPOINTS  ................................................................................................................................ 30  
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 5 of 65 9.2 SECONDARY ENDPOINTS  ........................................................................................................................... 30  
10.0  STATISTICAL CONSIDERATIONS .................................................................................................... ... 32 
10.1 PRIMARY ENDPOINTS AND HYPOTHESES  ................................................................................................... 32  
10.2 STATISTICAL SAMPLE SIZE JUSTIFICATIONS  .............................................................................................. 32  
10.3   STATISTICAL METHODS FOR PRIMARY ENDPOINTS  ................................................................................... 33  
10.4   SECONDARY STATISTICAL ENDPOINTS  ...................................................................................................... 33  
10.5 ASSUMPTION VERIFICATION  ..................................................................................................................... 34  
10.6 STUDY RETENTION AND HANDLING OF MISSING DATA ............................................................................ 34  
10.7 POOLABILITY  ............................................................................................................................................ 34  
10.8 SUBJECT POPULATIONS FOR ANALYSIS  ..................................................................................................... 35  
10.9 DETAILED STATISTICAL ANALYSIS PLAN .................................................................................................. 35  
10.10 STATISTICAL REFERENCES  ........................................................................................................................ 35  
11.0  RISK ANALYSIS ................................................................................................................. ....................... 36  
12.0  STUDY RESPONSI BILITIES ........................................................................................................ ........... 38  
12.1   RESPONSIBILITIES OF SPONSOR  ................................................................................................................. 38  
12.2   FDA  AND IRB  APPROVAL  ......................................................................................................................... 38  
12.3   SELECTION OF INVESTIGATORS  ................................................................................................................. 38  
12.4   SELECTION OF MONITORS  ......................................................................................................................... 38  
12.5   ACCOUNTABILITY AND CONTROL OF DEVICE  ........................................................................................... 38  
12.6   OBTAINING AGREEMENTS  .......................................................................................................................... 38  
12.7   INFORMING INVESTIGATORS  ...................................................................................................................... 38  
12.8   MONITORING INVESTIGATIONS  ................................................................................................................. 39  
12.9   RESPONSIBILITIES OF INVESTIGATORS  ....................................................................................................... 39  
12.10 SOURCE DOCUMENTATION  ........................................................................................................................ 39  
12.11 MAINTAINING RECORDS  ............................................................................................................................ 4 0 
12.12 STUDY DEVIATIONS  .................................................................................................................................. 41  
12.13 TERMINATION OF STUDY  ........................................................................................................................... 41  
13.0 STUDY COMM ITTEES ............................................................................................................................ 43  
13.1   DATA SAFETY MONITORING  ..................................................................................................................... 43  
13.2   CLINICAL EVENTS COMMITTEE  ................................................................................................................. 43  
14.0 TRAINING ...................................................................................................................... ............................ 44  
15.0 INFORMED CONSENT .............................................................................................................. .............. 45  
 
LIST OF APPENDICES  
Appendix I: References 
 Appendix II:  References Related to Complications 
 Appendix III:  ASA Cl assification System 
 Appendix IV: Schedule of Activities  Appendix V:  Informed Consent Template  Appendix VI:  CT Scanning Techniques  Appendix VII: Explant Procedure 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 6 of 65   
PROTOCOL SUMMARY 
Sponsor TriVascular, Inc. 
Protocol Title A Pivotal Clinical Study to Evaluate the Safety and Effectiveness of the 
Ovation Abdominal Stent Graft System 
Study Description A prospective, consecutively enrolling, non-randomized multi center clinical evaluation of the safety and efficacy of the Ovation Abdominal Stent Graft System when used in th e treatment of patients with AAA.  
Study Objectives The primary objectives of this study ar e to determine whether the Ovation 
Abdominal Stent Graft System is a sa fe and effective method of treating 
AAA’s in those patients considered to be suitable candidates for open surgical repair.    
The safety  of the Ovation Abdominal Stent Graft System will be 
determined by evaluating the proporti on of subjects that experience a 
Major Adverse Event. The Major Advers e Event rate will be compared to 
a performance goal.    The effectiveness  of the Ovation Abdominal Stent Graft System will be 
determined by evaluating the propor tion of subjects that achieve 
Treatment Success at 12 months post- procedure.  The Treatment Success 
rate will be compared to a performance goal. 
Study Primary 
Endpoints The primary safety endpoint is defi ned as the proportion of subjects who 
experience a Major Adverse Event within 30 days of the initial 
procedure.  The primary effectiveness endpoint is  proportion of subjects that achieve 
Treatment Success. Treatment Success is a composite endpoint assessed at 12 months that requires the following criteria to be met: 
 
- Technical Success, defined as succe ssful delivery and deployment of 
one aortic body and two iliac limbs. 
- Freedom from Type I & III endoleaks at 12 months 
- Freedom from stent graft migration at 12 months 
- Freedom from AAA enlargement at 12 months 
- Freedom from AAA rupture and conv ersion to open repair through 12 
months 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 7 of 65 PROTOCOL SUMMARY 
Study Secondary 
Endpoints The secondary safety  endpoints are: 
• Mortality rates at 30 days and 12 months  
• AAA related mortality at 30 days and 12 months 
• Major Adverse Events (MAE) through 12 months 
• AAA rupture through 12 months  
• Conversion to open repair through 12 months 
 The secondary effectiveness endpoints will be evaluated through 12 months:  
• Technical success, defined as successful delivery and deployment 
of one aortic body and two iliac limbs. 
• Freedom from Type I & III endoleaks  
• Freedom from stent graft migration 
• Freedom from AAA enlargement 
• Freedom from loss of  device integrity 
 
The secondary Clinical  Utility endpoints wi ll be evaluated: 
• Blood loss 
• Duration of procedure 
• Length of hospital stay 
• Type of anesthesia 
• Type of vascular access 
Subject Population Primary Study Phase - 150 subjects Continued Access Phase – 100 subjects 
Follow-Up Intervals Follow up intervals will consist of 1, 6, and 12 months following the initial implant procedure, then  annually through 5 years.   
Follow- Up Activities Follow up activities will consist of: 
• Physical exam  
• Ankle Brachial Index (ABI) at Hospital Discharge 
• Contrast Enhanced Spiral Abdominal/Pelvic CT  
• Abdominal X-ray (KUB), including AP, lateral, left oblique and 
right oblique views  
• Device/aneurysm assessment based on imaging  
• Laboratory Assessment  
• Assessment of Adverse Events  
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 8 of 65 PROTOCOL SUMMARY 
Investigational 
Sites Maximum of 40 sites 
 
Anatomic 
Criteria Proximal Neck Diameter: 16-30mm (ID) 
Proximal Neck Length: >7mm 
Juxtarenal Aortic Angle: < 45 degrees if <10mm neck length 
 ≤ 60 degrees if  >10mm neck length 
Iliac Diameter: 8-20mm 
Iliac Length: >10mm 
(Distal Seal Zone) Treatment Length: 13-19cm  
Principal 
Investigators: Dr. Manish Mehta 
Albany Medical Center 
Data Safety 
Monitoring Board (DSMB) Axio Research Acquisition Co. LLC  2601 4th Avenue, Suite 200  Seattle, WA 98121  Phone: 206-547-2829  Fax: 206-547-4671  
 
Monitoring TriVascular, Inc. 3910 Brickway Blvd. Santa Rosa, CA 95403 
Electronic Data Capture (Host) Phase Forward  880 Winter Street  Waltham, MA 02451  Phone: 781-890-7878  
Fax: 781-890-4848
  
Core Lab M2S, Inc.  
12 Commerce Avenue  West Lebanon, NH 03784 USA  Phone: 603-298-5509  
Fax: 603-298-5055
  
 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 9 of 65 PROTOCOL 
 
A list of all articles referenced in  this protocol is contained in Appendix I: References . 
1.0 STUDY GOAL  
The goal of this study is to ev aluate the performance of the Ovation Abdominal Stent Graft 
System in subjects with Abdominal Aortic Aneury sms.  The specific goals  of the study are to: 
1. Evaluate the safety of the Ovation Abdo minal Stent Graft System at 30, 180, 365-days 
and annually for 5 years post-implant. 
2. Evaluate the ability to deliver the Ovati on Abdominal Stent Graft System within the 
abdominal aorta. 
3. Evaluate the ability of the Ovation Abdominal Stent Graft to exclude the abdominal 
aortic aneurysm. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 10 of 65 2.0 BACKGROUND AND RATIONALE  
Abdominal aortic aneurysms (AAA) are the mo st commonly encounter ed aneurysm of the 
arterial system.  Several factor s are thought to contribu te to the development of AAA’s such as: 
advanced age, gender, previous family history of AAA, chronic obstructive pulmonary disease, 
hypertension, smoking, connective tissue disorders and atherosclerotic disease.  Males are 
affected by aneurysmal disease more often than females.   
The presentation of a AAA usually depends upon whether complications or symptoms have 
occurred.  Many asymptomatic patients are di agnosed with a AAA upon r outine examination by 
a physician for another problem or  as a result of increased patient awareness through public 
screening programs.  Symptoms such as acute onset  of abdominal, back, or flank pain are a result 
of expansion of the aneurysm.  Such symptoms can be an indication of  impending rupture which 
may follow at a time that is unpred ictable.  Rupture of a AAA is a life-threatening clinical event 
necessitating emergent interventi on.  Many patients with a ruptur ed AAA die before reaching the 
hospital.  Of the patients that  do reach the hospital, about ha lf of those patients survive.  
Fortunately, the rate of detecting and diagnosin g AAA has increased in recent years.  Improved 
imaging techniques and public screening programs for the aging population have contributed to 
this increase1.  
The overall objective in treating AAA is to preven t rupture and subsequent death.  The natural 
history of untreated AAA is to progressively enlarge and consequently rupt ure.  Although it is 
difficult to predict, it is genera lly accepted that the greater the diameter of a AAA, the greater the 
risk of rupture.  According to a study of 300 patients over a 6-year time period, Guirguis et al2  
determined that the risk of rupture of abdomina l aortic aneurysms with a diameter less than 5.0 
cm is significantly lower than the risk of rupture of AAA’s with a diameter  of 5.0 cm or more.  
More recently, Brewster et al3 reported in 2003 the risk of r upture for females having a 5 cm 
diameter AAA is equivalent  to that of a male ha ving a 6 cm diameter AAA. 
2.1 Conventional Treatment of Abdominal Aortic Aneurysm 
The current (standard) treatments for abdominal aortic aneurysms includ e “watchful waiting,” 
surgical repair of the aorta using a fabric substitute, and endovascular repair of the aorta. 
2.1.1  Watchful Waiting 
If the AAA is small and not causing symptoms , the treating physician may perform a CT or 
MRI scan every 6 months to assess changes in  the size or shape of the aneurysm.  This 
method is usually used for aneurysms that are smaller than about 5 cm in diameter. 
If the AAA is large, grows quickly, or is causi ng symptoms, it will require prompt treatment 
to prevent rupture.  The active treatments fo r AAA are open surgical aneurysm repair and 
endovascular stent graft repair. 
2.1.2  Open Surgical Repair 
Until the early 1990’s, open surgical repair was the only standard treatment for AAA.  
Significant inherent mortality and morbidity risk s are associated with open surgical repair 
due to the invasive nature of this surgery.  The standard surg ical procedure involves resection 
of the diseased segment of the aorta and replac ement with a synthetic graft.  This surgical 
technique necessitates general anesthesia, aortic cros s-clamping, and significant blood loss 
with associated transfusions.   
Improvements in mortality and morbidity rates fo r open surgical repair have been noted in 
the last several decades4.  The rate of early operative mortal ity for open surgical repair varies 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 11 of 65 greatly, (between 3-6 %) throughout the published litera ture.  In a prior FDA Health 
Notification, the repor ted range for early mortality rate s in population-based series for 
elective open surgical repair was between 3-5% at 30 days1.  In a literature review study 
conducted in 2001 by Hallin5, the mortality rate for elective su rgical repair was noted to be 
approximately 5%, and approximately 50% for emergent surgical repair.  In a recent multi-
center AAA clinical tr ial evaluation of open versus endova scular treatment conducted by W. 
L. Gore & Associates, Matusmura6 reports the rates of major adverse events were 
significantly lower in the endovasc ular group (14%) than those in  the control group (57%).  
Patients in the endovascular treatment group expe rienced less blood loss,  a reduction in need 
for transfusions and a shorte r length of hospital stay. 
Significant mortality and morbidity  have been associated with the surgical repair of AAAs, 
particularly in elderly patients with multip le comorbid medical conditions.  Surgical 
complications have mainly been associated with  the surgical incision, patient co-morbidities, 
cardiopulmonary bypass, and anticoagulation.  Postoperative complications have included 
bleeding, renal insufficiency, paraplegia, stro ke, and the need for prolonged ventilatory 
support.  The literature demonstrates mortality  rates for elective surgery to be 0–6.1%, with 
2.7% as the average.  The following outlines  morbidities associ ated with elective 
conventional surgery. 
Complication Range Average* 
All Cardiac (includes myocar dial infarction, congestive 
heart failure, and new cardiac arrhythmias) 0.8 – 21% 12% 
Pulmonary (includes pneumonia and pulmonary 
insufficiency, does not include atelectasis) 0 – 23% 8.4% 
Renal Failure (chronic and acute) 0 – 9% 4.2% 
Cerebrovascular Accident  0 – 11% 1.9% 
Paraplegia or Paraparesis 0 – 0.6% <0.1% 
Vascular 0 – 5.7% 1.1% 
Thrombotic/embolic 0 – 5.0% 1.8% 
Gastrointestinal 0 – 14% 4.2% 
Impotence 0 – 1.8% 0.2% 
Hematoma 0 – 1.8% 0.2% 
Bleeding/coagulopathy 0 – 44% 5.9% 
Wound healing/infection 0 – 7.1% 2.2% 
*Averages are unweighted from a review of the literature listed in Appendix II: References Related to 
Complications . 
 
2.1.3  Endovascular Stent Graft Repair 
Since the early 1990’s, endovascular abdominal aortic repair (EVAR) has evolved as an 
alternative treatment for AAA.  In 1991 Parodi was one of the first to  introduce endovascular 
aneurysm treatment as a less invasive procedure.  Since that time, systems for performing 
endovascular repair of AAA have been deve loped, improved upon, clinically tested, and 
approved by FDA for commercial use.  The availability of this less invasive technique has 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 12 of 65 afforded the treatment of patients with multiple co-morbidities.  These patients may have 
otherwise been excluded from treat ment with open surgical repair7. 
Endovascular grafts, often stented for support, are designed to provide an alternate conduit 
for blood flow and should exclude the aneury sm from this flow and the associated 
hemodynamic pressure.  Exclusion of the aneury sm is presumed to significantly reduce its 
potential for rupture. 
Endovascular repair of AAA invol ves the placement of a stent graft at the location of the 
aneurysm without the need for performing an open surgical procedure.  This technique is less 
traumatic for the patient by eliminating the need  for aortic clamping, thereby eliminating or 
reducing the risks associ ated with decreased blood flow to vital organs and to the lower 
extremities.  Additionally, anesthetic and ventilation time during these procedures are 
reduced.  An endovascular approach also elim inates a significant amount of postoperative 
pain and discomfort associated w ith that of open surgical repair  and allows a s horter recovery 
time for the patient.  The length of hospital st ay is reduced, thus, allo wing patients to more 
rapidly resume their normal activities of daily living.   
During the last 10 years, systems for perfor ming endovascular repair  of AAA have been 
developed, clinically tested, and approved for use.  At the present time, there are 
approximately five (Excluder, Zenith, Powerlink, Talent, AneuRx) devices approved for use 
in the United States, six to eight devices appr oved for use in Europe, and several devices 
approved for use in Australia.  The follo wing outlines morbidities associated with 
endovascular repair.  
Complication Range Average* 
All Cardiac (includes myocar dial infarction, congestive 
heart failure, and new cardiac arrhythmias) 0 – 12% 4.9% 
Pulmonary (includes pneumonia and pulmonary 
insufficiency, does not include atelectasis) 0 – 7.7% 2.6% 
Renal Failure (chronic and acute) 0 – 6.5% 3.0% 
Cerebrovascular Accident  0 – 2.8% 0.3% 
Paraplegia or Paraparesis 0 – 0.2% <0.1% 
Access/Deployment Failure 0 – 11% 5.0% 
Endoleak 6.5 – 47% 21% 
Vascular 0 – 14% 5.1% 
Thrombotic/embolic 0.9 – 18% 7.7% 
Gastrointestinal 0 – 4.8% 1.4% 
Impotence 0% 0% 
Hematoma/bleeding/coagulopathy 0 – 24% 5.7% 
Wound healing/infection 0 – 14% 3.0% 
*Averages are unweighted from a review of the literature listed in Appendix II: References Related to 
Complications . 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 13 of 65 The literature demonstrates mortality rates for endovascular repair to be 0–7.5%, with 3.4% 
as the average.  This rate is inflated, to some extent, by the u tilization of endovascular repair 
in patients who are not candidates for surgic al repair because of co–morbidities that 
dramatically increase the risk associated with  the surgical procedure.  For the systemic 
morbidities (cardiac, pulmonary, renal, cerebrovascular, and gastrointestinal), the rates for 
endovascular repair appear to be lower than for surgical repair.  The statistical significance of 
this observation, however, has not been assessed. 
During the clinical evaluation of the AneuRx St ent Graft System for AAA repair, patients in 
the endovascular repair group ha d lower blood loss, fewer days in the ICU, and a shorter 
hospitalization in comparison to the patients in the surgical control group.  The difference for 
each of these measures was statistically signific ant.  Similarly, the clinical evaluation of the 
ANCURE System demonstrated that the endovascular repair group experienced a statistically 
significant lower blood loss and a shorter hospitalization than the patients in the surgical 
control group. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 14 of 65 3.0 INDICATIONS 
The Ovation Abdominal Stent Graft System is indi cated in subjects diagnosed with an aneurysm 
in the abdominal aorta having vascular morphology suitable for endovascular  repair, including: 
• Adequate iliac/femoral access compatible wi th vascular access techniques, devices, 
and/or accessories, 
• Non-aneurysmal proximal aortic neck: 
o with a length of at least 7 mm proximal to the aneurysm, 
o with an inner wall diameter of no less than 16 mm and no greater than 30 mm, 
and 
o with an aortic angle of <60 degrees if proximal neck is ≥10 mm and <45 degrees 
if proximal neck is <10 mm, 
• Non-aneurysmal distal iliac landing zone: 
o with a length of  at least 10 mm, 
o with an inner wall diameter of no less  than 8 mm and no greater than 20 mm. 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 15 of 65 4.0 DEVICE DESCRIPTION 
The TriVascular Ovation™ Abdominal Stent Graft System is  a low-profile endovascular device 
delivered via catheter to treat abdominal aortic aneurysms (AAAs).   The stent graft is designed to 
reline the diseased vasculature, providing an alternate endovascular blood conduit for isolating 
the aneurysm from the high pressure flow of bl ood, thereby reducing or eliminating the risk of 
rupture.  The stent graft is a modular configuration comprised of  an aortic body section, iliac 
limbs, and iliac extensions as required (Figure 1).    The aortic section is compri sed of a proximal stent for s upra-renal fixation and a low-
permeability PTFE graft.  The stent is designed with small anchors to enable fixation to the aortic wall.  For delivery, the stents are in a co mpressed state within the ca theter.  When released 
from the compressed state, the stent expands to engage the vessel wall.  The nitinol stents are radiopaque and the implant contains radiopaque markers adjacent to the graft edges.  These 
markers serve as positioning aids during placeme nt of the device and allow the stent to be 
located so that it will not obstruct the renal arteri es.  To seal the proximal end of the graft and to 
provide support into which the iliac limbs ar e deployed, the graft body contains a network of 
inflatable rings that are filled with a liquid polymer which solidifies during the deployment procedure.  The graft has a fill port that connects the fill networ k of the graft to the delivery 
catheter.    The iliac limbs and extensions are comprised of n itinol stents encapsulated in PTFE.  The limbs 
are deployed into the limb section of the aortic  body.  Radiopaque markers allow the physician to 
visualize the appropriate iliac limb - aortic body overlap or ili ac extension – iliac limb overlap 
during a catheter-based deployment.  Stent radial  force provides both fixation and sealing of the 
interface between the aortic body and each iliac limb, between the i liac limb and iliac extension, 
and between the iliac limb/extension and its landing zone in the iliac artery. 
 
 
Figure 1. Schematic of Deployed Ovation Abdominal Stent Graft  System 
 
To facilitate device introduction into the access vessel, th e aortic body, the iliac limbs and the 
iliac extensions are preloaded into low-profile delivery cath eters (14F-15F OD, 13F–15F OD, 
and 13F-14F OD respectively; Figures 2 and 3).  The aortic body is deploye d via the aortic body 
delivery catheter.  The aortic body delivery cathete r has a lumen that allows for the use of a 
guidewire to help deliver the sten t graft to the deployment site.   
 During stent graft deployment, the device is positioned and the shea th is retracted.  The proximal 
stent is then deployed using release knobs on the handle.  The fill polymer is then delivered through the fill connector port using an auto injector (supplied).   
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 16 of 65  
The contralateral and ipsilateral iliac limbs are de ployed via iliac limb deliv ery catheters.  After 
deployment of the aortic body, a guidewire is placed  from the contralateral access site into the 
contralateral distal leg of the aortic body.  The contra lateral iliac limb is then advanced into 
position and deployed into the aortic body by retracting the catheter sheath with the catheter in the appropriate location.  After the fill material  cures within the sealing rings, the aortic body 
delivery catheter is disengaged from  the fill port of the graft and w ithdrawn from the vasculature.  
The ipsilateral limb is then advanced over the ipsilateral guide wire and deployed using the 
method described above for the contralateral limb.  If an iliac extension is required, the delivery system is advanced over the guide wire and deployed using the method described above for contralateral and ipsi lateral iliac limbs. 
    
Figure 2. Schematic of TriVascular Ovation St ent Graft aortic body delivery catheter 
   
 
 
Figure 3. Schematic of TriVascular Ovation Stent Graft iliac limb/extension delivery 
catheter  
 
The fill polymer is comprised of three components and is supplied in kit form as shown in Figure 
4.  Upon mixing and injection into the graft, the components form a robust radiopaque polymer 
network that is durable in vivo .  Once inside the PTFE  channels in the wa ll of the aortic body 
graft, the fill polymer forms conformable “gasket-like” sealing rings.  The fill polymer 
radiopacity dissipates over time and may not be visible on fluoroscopy beyond 1-2 months post-
implant.   

TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 17 of 65  
Just prior to use, the two valves  on the kit are opened and the f ill polymer is mixed by alternately 
depressing the two syringe plungers for a total of 15 strokes.  Thereafter, the full syringe is 
disconnected from the connection tube, slipped out of the syringe  support and co nnected to the 
fill polymer injection port on the catheter handle.  The syringe plunger is then inserted into the 
autoinjector (Figure 5) and the syringe given a quar ter-turn to lock it in place.  The autoinjector 
applies controlled pressure to in ject the fill polymer into the graft without requiring continuous 
attention from the operator.  
 
Figure 4 – TriVascular Fill Polymer Kit 
  
 
Figure 5–TriVascular Autoinjector 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 18 of 65 5.0 STUDY DESIGN 
This is a Phase II prospective, consecutive  enrolling, non-randomized multi-center clinical 
evaluation of the safety and effectiveness of the TriVascular Stent Graft when used in the 
treatment of patients with AAA.  
A total of 150 subjects will be enrolled during the primary study phase with an additional 100 
subjects enrolled during the continued access phase at up to 40 institutions.  No one institution 
may enroll more than 30 subjects.   
5.1 Eligibility Criteria 
5.1.1  Inclusion Criteria 
All patients must meet all of the following inclusi on criteria to be eligible for enrollment into 
this study: 
1. Patient is > 18 years of age 
2. Patients who are male or non-pregnant female  (females of child bearing potential must 
have a negative pregnancy test pr ior to enrollment into the study) 
3. Patient has signed an Institutional Review Board (IRB) approved Informed Consent Form 
4. Patient is considered by the treating physician to  be a candidate for elective open surgical 
repair of the AAA (i.e., category I, II, or III per American Society of Anesthesiology 
(ASA) classification; refer to Appendix III: ASA Classification System ).  ASA 
category IV patients may be enro lled provided their life expect ancy is greater than 1 year. 
5. Patient has an infrarenal abdominal aortic aneurysm that meets at least  one of the 
following: 
• Abdominal aortic aneurysm >5.0 cm in diameter  
• Aneurysm has increased in size by 0.5 cm in last 6 months.  
• Maximum diameter of aneurysm exceeds 1.5 times the transverse dimension of an 
adjacent non-aneurysmal aortic segment 
6. Patient has patent iliac or femoral arteri es that allow endovascular access with the 
TriVascular Ovation Abdominal Stent Graft System. 
7. Patient has a suitable non–aneurysmal proximal aortic neck length of > 7 mm inferior to 
the most distal renal artery ostium. 
8. Patient has a suitable non-aneurysmal distal  iliac artery length (seal zone) of >10 mm. 
The resultant repair should preserve pate ncy in at least one hypogastric artery.  
9. Patient has a suitable non–aneurysmal proximal  aortic neck luminal diameter between 16 
and 30 mm.  
10. Patient has suitable non–aneurysmal distal i liac luminal diameters between 8 and 20 mm. 
11. Patient meets the following anatomic criteria:  the distance from the most distal renal 
artery to most superior internal iliac artery measurement is at least 13 cm.   
12. Patient has juxtarenal aortic neck angulation < 60º if proximal neck is ≥10 mm and < 45º 
if proximal neck is <10 mm.  
13. Patient must be willing to comply with all required follow-up exams. 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 19 of 65 5.1.2  Exclusion Criteria 
Patients that meet ANY of the following are not eligible for enrollment into the study: 
1. Patient has a dissecting aneurysm  
2. Patient has an acutely ruptured aneurysm 
3. Patient has an acute vascular injury 
4. Patient has a need for emergent surgery  
5. Patient has a known thoracic aort ic aneurysm or dissection. 
6. Patient has a mycotic aneurysm or has an active systemic infection  
7. Patient has unstable angina (defined as angina  with a progressive increase in symptoms, 
new onset at rest or nocturnal angina, or onset of  prolonged angina) 
8. Patient has had a myocardial infarction (MI) and/or stroke (CVA) within the past 6 
months. 
9. Patient has a major surgical or interventional procedure planned ≤30 days of the AAA 
repair. 
10. Patient has history of connective tissue di sease (e.g., Marfan’s or Ehler’s–Danlos 
syndrome). 
11. Patient has history of bleeding disord ers or refuses blood transfusions.  
12. Patient has dialysis dependent renal failure or baseline serum crea tinine level >2.0 mg/dl 
13. Patient has a known hypersensitivity or cont raindication to anticoa gulation or contrast 
media that is not amenable to pre-treatment. 
14. Patient has a known allergy or intolerance to polytetrafluorethylen e (PTFE), PEG-based 
polymers, fluorinated ethylene propylene (FEP) or nitinol. 
15. Patient has a body habitus that would inhi bit X–ray visualization of the aorta 
16. Patient has a limited life expectancy of less than 1 year 
17. Patient is currently participat ing in another inves tigational device or drug clinical trial  
18. Patient has other medical, social or psychol ogical conditions that, in the opinion of the 
investigator, preclude them from receiving th e pre-treatment, required treatment, and 
post-treatment procedures and evaluations.  
5.2 Study Population 
5.2.1  Subject Selection Adult male and female patients will be cons ecutively screened for the study.  Eligible 
patients must meet all of the inclusion crit eria and none of the ex clusion criteria.   
 
The study includes 150 subjects enrolled durin g the primary study phase with an additional 
100 subjects enrolled during th e continued access phase.     
5.3 Withdrawal and Lost-to-Follow-Up 
Subjects may be withdrawn from the study for any of the following reasons:   
• Lost-to-follow up despite exhaustive attempts  to contact.  A minimum of three (3) 
attempts to contact such subjects must be  made.  One such attempt must include a 
registered return receipt reque sted letter. All attempts to contact the subjects must be 
documented.  
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 20 of 65 • Subjects may voluntarily decide to withdraw  from the study. All reasonable attempts 
should be made to ascertain the reason for voluntary withdrawal. 
 
All subject withdrawals must be documented on the Study Completion/Exit Case Report Form 
(eCRF) . 
5.4 Duration of Study 
Subject follow-up visits will occur at one, six, and 12 months post implant procedure then 
annually through five years.  Lifelong follow-up by the physician is required after subjects have 
completed the study. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 21 of 65 6.0 STUDY PROCEDURES 
Treatment of subjects enrolled in this study will include tests and procedures listed in Appendix 
IV: Schedule of Activities .  Placement of the AAA stent graf t will be perfor med in accordance 
with the IFU.   
6.1 Patient Screening 
Prospective candidates are evaluated in a consec utive manner for eligibility for the study at the 
time they are considered to be candidates fo r AAA repair.  Initial screening may include 
diagnostic testing (e.g., imaging, angiogram, laborat ory testing) performed as part of routine 
medical care.   
 The following steps outline the process to determ ine patient eligibility for enrollment and 
subsequent shipment of the device(s): 
1. Ensure that patient has signed an IRB approve d Informed Consent Form, per Institutional 
policies 
2. Complete the Eligibility Ve rification Worksheet form  
3. Complete the AAA Pre-Operative Sizing Worksheet  
4. Fax #2 and #3 (above) to TriVascular Clinical Department (888-706-1617) 
5.  Submit contrasted spiral CT images to Core  Lab obtained within 6 months of anticipated 
treatment. 
Refer to Manual of Operations for Core Lab Imaging Guidelines. 
6.2 Pre-procedure evaluation 
The following assessments will be performed no more than one month prior to the 
implant/surgical procedure:   
• Patient demographics  
• Medical/surgical history 
• Physical exam 
• Ankle-Brachial Index (ABI) measurement 
• Laboratory testing, which includes renal and coagulation assessment, as well as serum 
pregnancy for female patients of childbearing potential.  
 
If the patient is eligible to be enrolled into the study, the results of these screening assessments 
are recorded on the Baseline eCRF. If a patient does not qualify for enrollment into the study, 
the baseline screening worksheets will be retain ed, together with the patient’s signed/dated 
consent(s).    
6.3 Treatment period (implant/surgical procedure) 
The following assessments and data collection will be performed at the time of the 
implant/surgical procedure: 
• Investigational device account ability- documentation of product information (e.g., lot 
number, serial number, and expiration date).  
• Type and length of anesthesia 
• Anticoagulation 
• Description of delivery system access on both ipsilateral and contralateral sides (e.g. 
femoral cut down, percutaneous access, closure device) 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 22 of 65 • Type and volume of contrast used 
• Total fluoroscopy time during procedure 
• Estimated blood loss and replacement requirements 
• Adjunctive procedures (e.g. stent placement) 
• Investigator assessment of AAA devi ce performance as it relates to: 
o Access success/failure, delivery/deploym ent success, evidence of endoleak, 
device integrity issues  
• Procedural times  (time of initial arterial access, stent graft deployment start and stop 
time, polymer mix completion time, delivery system removal time, and time of closure of 
arterial access) 
• Adverse events  
6.4 Pre-Discharge  
The following assessments and testing will be performed post-procedure, prior to discharge: 
• Physical exam 
• Ankle-Brachial Index (ABI) measurement 
• Laboratory testing, which includes renal and optional coagulation assessment  
• Length of hospital stay 
• Abdominal X-ray (KUB), includi ng AP, lateral, left oblique a nd right oblique views. This 
X-ray will serve as the baseline for all future  evaluations of device integrity and can be 
performed within 7 days fo llowing hospital discharge. 
• Concomitant medications (anticoagulants, antiplatelets and antibiotics only) 
• Adverse events  
• Other relevant data as indicated on th e CRF, including optional wound assessment. 
The above assessments are recorded in the Hospital Discharge eCRF.  In some instances, 
subjects may experience a prolonged hospitalizati on post procedure.  In those cases, the above 
assessments should be performed no more  than two (2) weeks post procedure. 
6.5 Post-Treatment follow-up period The following assessments and tests will be performed at the following intervals: 
 
Time period post-treatment Acceptable visit ti meframe allowance 
1 Month (30 days) ± 14 days 
6 Months (180 days) ± 30 days 
12 Months (365 days) ± 60 days 
Annually from 2 to 5 years ± 60 days 
 
• Physical exam 
• Laboratory testing, which includes rena l and optional coagulation assessment  
• Contrast Enhanced Spiral Abdominal/Pelvic CT 
• Abdominal X-ray (KUB), including AP, lateral, left oblique and right oblique views 
Device/aneurysm assessment based on imagi ng (endoleak, migration, integrity, patency, 
AAA dimensions)  
• Concomitant medications (anticoagulants, antiplatelets and antibiotics only) 
• Adverse events  
• Other relevant data as indicated on th e CRF including optional wound assessment. 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 23 of 65 The above assessments are re corded in the appropriate Follow-up Visit eCRF.  Note that in the 
event the subject is unable to  tolerate a contrast-enhanced spiral CT, a duplex ultrasound and 
non-contrast spiral CT should be  completed as an alternative assessment.  
6.6 Unscheduled Follow-up visits 
In the event that a subject visit occurs outside  the protocol-specified  time frames (i.e., Pre-
discharge, 1 month, 6 month, 12 month)  sites are required to record data from that visit, if that 
visit is specifically associated with the devi ce, procedure or aneurysmal disease.  Possible 
reasons for unscheduled vis it data collection may be: 
• Subject experiences new symptoma tology and/or an adverse event 
• Surveillance of an existing adverse event 
 
The Unscheduled visit informati on would be recorded in the Follow-up Visit eCRF where the 
reason for the unscheduled visit will be specified. 
 
If a subject is seen in the office or clinic for other reasons than listed above, information from that visit would be recorded on the next protocol-specified vis it in the appropriate Follow-Up 
CRF.    
6.7 Annual follow-up visits 
Subjects who have completed 12 months of fo llow-up will continue annual follow-up exams  
(+/- 2 months) for 5 years.  
 The following assessments and tests will be pe rformed at annual visits through 5 years: 
 
• Physical exam 
• Laboratory testing, which includes rena l and optional coagulation assessment  
• Contrast Enhanced Spiral Abdominal/Pelvic CT 
• Abdominal X-ray (KUB), including AP, lateral,  left oblique and right oblique views  
• Device/aneurysm assessment based on imagi ng (endoleak, migration, integrity, patency, 
AAA dimensions)  
• Concomitant medications (anticoagulants, antiplatelets and antibiotics only) 
• Adverse events  
• Other relevant data as indicated on th e CRF, including optional wound assessment. 
6.8 Discontinuation from study 
Subjects who choose to discontinue  participation in the study pr ior to study completion will be 
requested to undergo a final assessment by the inve stigator at the time no tification is made of 
their decision to discontinue.  If  the subject notifies the clinical site of discontinuation by mail or 
phone, subject will be requested to have a final assessment by the investigator.   
 
The final assessment will be recorded in the Follow-up Visit and Study Completion/Exit 
eCRFs. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 24 of 65  
7.0 STUDY OBJECTIVES 
The purpose of this pivotal clinical trial is to evaluate the safety and effectiveness of the Ovation 
Abdominal Stent Graft in the treatment of subj ects with abdominal aortic aneurysms (AAA). 
7.1 Primary Objectives 
The primary objective of this study is to dete rmine whether the Ovati on Abdominal Stent Graft 
System is a safe and effective method of treat ing AAAs in those subjects considered to be 
suitable candidates for ope n surgical repair.   
 
The safety of the Ovation Abdominal Stent Gr aft System will be dete rmined by proportion of 
subjects with major adverse events.  The effectiveness of the Ovation Abdominal St ent Graft System will be determined by the 
proportion of subjects that achieve treatment success. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 25 of 65 8.0 DEFINITIONS 
8.1 Endoleak 
Endoleak is defined by the persistence of blood fl ow outside the lumen of the endovascular graft 
but within the aneurysm sac and can be classified as: 
Type I  – Ineffective seal at either the proximal or distal sealing zones 
Type II – Retrograde blood flow from lumbar arteries, the inferior mesenteric artery, or other 
collateral vessels into the aneurysm sac 
Type III – A leak caused by fabric tears or disr uption, component disconnection, or graft 
disintegration 
Type IV – Blood flow through an intact fabric.  
8.2 Migration 
Migration is defined as evidence of proximal or  distal movement of the stent graft >10mm 
relative to fixed anatomic landmarks. Spiral CT images will be used to determine migration at 
regularly scheduled follow-up visits.  The 1 month image wi ll be used as the baseline 
assessment. 
8.3 Patency 
Patency is defined as the absenc e of complete occlus ion of the treated vessel.  This may be 
evidenced by: CT, angiography, ultrasound or other imaging modality, or pathological analysis. 
8.4 Loss of Stent Graft Integrity The integrity of the stent graft will be evalua ted by abdominal x-rays at regularly scheduled 
follow-up visits.  Any fractured stents, and any other issues compromisi ng the integrity of the 
stent graft will be reported.  
8.5 AAA Enlargement Aneurysm enlargement is defined as a greater than 5 mm (diameter) increase in the aneurysm 
size.  Spiral CT images will be used to determ ine aneurysm enlargement at regularly scheduled 
follow-up visits.  The 1 month image will be used as the baseline assessment. In addition, 
aneurysm volume will be assessed by the Core Lab and reported in the data analysis, but 
diameter is considered the relevant char acteristic for the st udy endpoint evaluations. 
8.6 Surgical Conversion 
Surgical conversion occurs when a subject impl anted with an Ovation Abdominal Stent Graft 
undergoes open surgical repair with explantation of the stent graft. The follow-up for subjects 
who are converted to open surgic al repair include collection of  the following data: Physical 
Exam and assessment of Adverse Events.  Th e visits are to occu r at 1 month post open 
conversion and 1 year po st open conversion.   
8.7 Imaging Core Lab 
TriVascular will utilize an independent imag ing Core Lab to analyze device performance 
specifically related to study endpoints such as: device inte grity, endoleaks, migration, and 
aneurysm dimensions (e.g., lengt h, diameter, volume).  Clinical  sites will submit all CT and X-
ray images to the Core Lab fo r all required study visits.   
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 26 of 65 Study Visit Images* Required to  be submitted to Core lab 
Baseline 
(pre-op) Contrast Enhanced Spiral Abdominal/Pelvic CT  
Discharge (post-op) Abdominal X-rays (AP, la teral, left oblique and 
right oblique views ) 
1 month (16 - 44 days) Abdominal X-rays (AP, la teral, left oblique and 
right oblique views ) Contrast Enhanced Spiral Abdominal/Pelvic CT 
6 month (150 - 210 days) Abdominal X-rays (AP, la teral, left oblique and 
right oblique views ) Contrast Enhanced Spiral Abdominal/Pelvic CT 
12 month (305 - 425 days) Abdominal X-rays (AP, la teral, left oblique and 
right oblique views ) Contrast Enhanced Spiral Abdominal/Pelvic CT 
*
Refer to Appendix VI: CT Scanning Techniques  and Manual of Operations 
for Core Lab imaging requirements. 
8.8 Explant Evaluation 
TriVascular is committed to unders tanding the effects of the human in vivo  environment on the 
stent graft over time.  To this end, all explante d devices should be returned to TriVascular for 
evaluation by a Pathologist at an inde pendent Explant Laboratory.  Refer to Appendix VII: 
Explant Procedure  and the Manual of Operations for sp ecific instructions for managing the 
removal, shipping, and handling of the explanted AAA device.  
8.9 Adverse Events 
An adverse event is any new, undesirable medical  occurrence or change (worsening) of a pre-
existing condition that occurs in a subject, whether or not considered to be associated with the 
product.  Elective hospitalizations for pre-existi ng conditions (e.g., elective cosmetic procedures) 
are not adverse events.   
 Requirements for reporting AEs are dependent upon the reviewing IRB policy. Adverse events 
will be reviewed by a Clinical Events Committ ee (CEC).  The CEC will meet periodically, a 
minimum of annually.  Adverse Event information is recorded in the Adverse Event eCRF . 
For purposes of this study, the following events ar e not considered adverse events, because they 
are expected to occur in conjunc tion with the index procedure or are associated with customary, 
standard care of subjects undergoing endovascular AAA repair procedures: 
 Early post-operative pain (within 24 hours of index procedure) at the access site 
and/or related to position on procedure table 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 27 of 65  Post-anesthesia/conscious sedation emesis, nausea, or headache (within 24 hours of 
index procedure) 
 Electrolyte imbalance without clinical seque lae following index procedure, even if 
requiring correction 
 Low grade temperature increase (< 101.0 °F) 
 Hematocrit decrease from baseline of less th an 6 points (2 grams of hemoglobin) that 
remains above 30% and is not associated  with hemodynamic changes and does not 
require transfusion 
 Blood loss not requiring transfusion and not resulting in decreased hematocrit. 
 Minor, localized tenderness, swelling, induration, bruising, erythema, hematoma etc. 
at vascular access site that does not requi re surgical intervention, evacuation, 
transfusion, or antibiotics 
 Prophylactic administration of atropine 
 Prophylactic pacing 
 Isolated, non-sustained PVCs/PACs 
 Non-sustained, arrhythmia not re quiring treatment or intervention 
 Hypotension or hypertension not requ iring treatment or intervention 
 Atelectasis not requiring treatment 
 
The Investigator and/or IRB may require that these events are reported as adverse events.  In this 
case, the Investigator should report these observations based on their medical judgment and 
requirements of the IRB.  
Device-related adverse events should be rep orted to the sponsor within 24 hours of 
knowledge of the event. 
 
8.10 Serious Adverse Events (SAE) 
A serious adverse event (SAE) defined as one th at suggests a significant hazard or side effect, 
regardless of the investigator  or sponsor’s opinion on the rela tionship to the investigational 
product.  This includes, but may not be limited to, any event that: 
• Is fatal 
• Is life-threatening 
• Requires or prolongs  (>48 hour s) inpatient hospitalization 
• Is a persistent or signific ant disability or incapacity 
• Is considered an important medical event 
 
Important medical events may be considered se rious by the investigator  although they may not 
be immediately life threat ening or result in death or prolong hospitalization.  Such important 
medical events are those that may jeopardize the subject, require interven tion to prevent one of 
the outcomes listed above, or result in urgent investigation.  Examples include, but are not 
limited to, allergic bronchospasm, convulsions, and blood dyscrasias. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 28 of 65   
Serious Adverse Events will be recorded in th e Adverse Event CRF and the event is to be 
reported by telephone or fax to the Sponsor wi thin 24 hours of knowledge of the event.  
Sites are also required to adhere to the reviewing IRB requirements for reporting of SAE’s. 
8.11 Major Adverse Events (MAE) 
The following specific events will be considered  major adverse events (MAE) for the purpose of 
evaluating the primary (30 day) and s econdary (1 year) safety endpoints: 
 
Major adverse events (MAE) are defined as any one of the following events: 
• Death 
• Myocardial Infarction 
• Stroke (excludes TIA) 
• Renal Failure (excludes renal insufficiency) 
• Respiratory Failure (excludes CO PD or pulmonary complications) 
• Paralysis (excludes paraparesis) 
• Bowel Ischemia 
• Procedural Blood Loss ( ≥1,000 cc) 
 
A major adverse event (MAE) may or may not be considered related to the device. Mortality will 
be reported as “all cause” and “AAA related.” All deaths occurring in the first 30 days post-
index procedure are cons idered “AAA related.” 
 The Clinical Events Committee (CEC) shall determine which adverse events are considered Major Adverse Events (MAE) for evaluation of the primary (30 days) and secondary (1 year) 
safety endpoints.   
8.12 Unanticipated Adverse Device Effect (UADE) 
An unanticipated adverse device effect means any serious adverse effect on health or safety or 
any life-threatening problem or death caused by, or  associated with, a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the 
investigational plan or application (including a supplementary plan or applicatio n), or any other 
unanticipated serious problem associated with a device that relates to the rights, safety, or 
welfare of subjects.  
 
Unanticipated Adverse Device Effect (UADE) a re to be recorded in the Adverse Event CRF 
and the event is to be reported by telephone or fax (see above contact information) to the 
Sponsor within 24 hours of knowledge of the even t.  Sites are also required to adhere to the 
reviewing IRB requirements for reporting of any UADE. 
8.13 Conversion to Open Surgical repair 
Conversion to open surgical repair may occur either at the initial implant procedure or 
subsequent to the initia l procedure.  Information regardin g the surgical c onversion will be 
recorded on the Open Surgical Conversion eCRF and the Adverse Event eCRF .    
 
In the event that a subject requires conversion from endovascular to open surgical repair, the 
explanted device should be sent  to TriVascular for examina tion.  Refer to the Manual of 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 29 of 65 Operations for specific instructions for mana ging the removal, shipping and handling of the 
explanted device.  Explant information will be recorded on the Explant eCRF. 
 
Surgical conversions must be reported by telephone or fax to the Sponsor within 24 hours  of 
knowledge of the event. 
 The Follow-up visit schedule for surg ically converted subjects is at one month and one year post 
open conversion.  
8.14  Technical Failures   
In the event that an AAA stent graft could not be deployed due to a te chnical failure, contact 
TriVascular Clinical Affairs to obtain device return information. Device failure information will 
be captured on the Device Failure eCRF . 
8.15 Deaths  
Any deaths that occur du ring the conduct of the study must be reported by telephone or fax to the 
Sponsor within 24 hours  of knowledge of the event.  Sites are also required to adhere to the 
reviewing IRB requirements for reporting of deat hs.  In addition, subject s with an implanted 
device who expire before completing the study should have the device explanted and sent to 
sponsor whenever possible for examination.  Ad ditional information to be submitted to sponsor 
may include such documents as: death certificat e, autopsy report, summary of death report, 
hospital records, explant reports and c opy of IRB notification of the event. 
8.16 Explants Specific instructions for managing the removal, shipping and handling of the explanted device 
can be found in Appendix VII: Explant Procedure and Manual of Operations.  Explant 
information will be recorded on the Explant eCRF . 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 30 of 65 9.0  ENDPOINTS AND TECHNIQUES FOR MEASUREMENT 
For the purpose of this study, the information below provides definitions and measurement 
criteria in determining each endpoint. The endpoints (primary and secondary) specified below 
and Statistical Considerations outlined in S ection 10 may appear in the product labeling to 
support clinical results. Informa tion not included in the endpoint  list below or the statistical 
considerations will not a ppear in the labeling to support clinical results. 
9.1 Primary Endpoints 
9.1.1  Safety 
The primary safety endpoint is the rate of major adverse events (MAE) at 30 days post 
procedure. The following specific events will be considered major adverse events: 
 
Major adverse events (MAE) are defined as any one of the following events: 
• Death 
• Myocardial Infarction 
• Stroke (excludes TIA) 
• Renal Failure (excludes renal insufficiency) 
• Respiratory Failure (excludes CO PD or pulmonary complications) 
• Paralysis (excludes paraparesis) 
• Bowel Ischemia 
• Procedural Blood Loss ( ≥1,000 cc) 
 
A major adverse event (MAE) may or may not be considered related to the device. Mortality will be reported as “all cause” a nd “AAA related.” All deaths occurring in the first 30 days 
post-index procedure are considered “AAA related.”  
9.1.2  Efficacy 
The primary effectiveness endpoint is the pro portion of subjects that achieve treatment 
success. Treatment success is a composite endpoint assessed at 12 months that requires all of 
the following criteria to be met in order for a subject to be considered a treatment success: 
 
• Technical Success, defined as successful deliv ery and deployment of one aortic body and 
two iliac limbs. 
• Freedom from Type I & III endoleak at 12 months 
• Freedom from stent graft migration at 12 months 
• Freedom from AAA enlargement at 12 months 
• Freedom from AAA rupture and conversi on to open repair through 12 months 
9.2 Secondary Endpoints 
9.2.1  Safety The following secondary safety endpoints will be assessed: 
 
• All-cause mortality at 30 days and 12 months 
• AAA Related Mortality at 30 days and 12 months 
• Major Adverse Events (MAE) through 12 months 
• AAA rupture through 12 months 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 31 of 65 • Surgical conversion through 12 months 
 
All deaths that occur in the st udy will be adjudicated by the CE C.  AAA related death is any 
death determined by the CEC to occur as a result of the initial procedure (first 30 days), AAA 
rupture, conversion to open surgical repair, or any AAA re lated secondary intervention. 
 
 
9.2.2  Stent Graft Efficacy   
The following secondary efficacy endpoints will be assessed. 
1)  Technical Success   
The physician was able to insert the delivery catheter and deliver an aortic graft and two 
iliac limbs to the treatment site. 
2)  AAA Enlargement Any increase in aneurysm diameter (>5 mm) from the one month (baseline) post-
operative measurement will be considered AAA enlargement, as determined by Core 
Lab.   3)  Migration Migration is defined as eviden ce of proximal or distal movement of the stent graft >10 
mm relative to fixed anatomic landmarks.  Spir al CT images will be used by Core Lab to 
determine migration from the one month (baseline) CT image. 4)  Type I and III Endoleak Type I and III endoleaks will be assessed by th e Core Lab using Spiral CT images.   
5)  Device Integrity The integrity of the stent graft will be evalua ted from X-ray images by the Core Lab using the 
discharge X-ray as the baseline.  Any fractured st ents or other issues compromising the integrity 
of the stent graft will be reported. 
9.2.3  Clinical Utility Assessment  
The following secondary endpoints associated w ith the procedure will also be assessed: 
• Procedure time  
• Amount of blood loss 
• Days spent in hospital 
• Type of Anesthesia 
• Type of Vascular access 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 32 of 65 10.0  STATISTICAL CONSIDERATIONS 
10.1 Primary Endpoints and Hypotheses 
10.1.1  Primary Safety Endpoint and Hypothesis: Major Adverse Event Rates 
This study is designed to compare the rate of major adverse events following abdominal 
aortic aneurysm repair with the Ovation Abdominal Stent Graft System to a target 
performance goal.  The proporti on of subjects receiving the Ov ation Abdominal Stent Graft 
who experience one or more events meeting the definition of a major adverse event within 30 
days of the initial procedure is the rate of interest.   The nu ll and alternative hypotheses are 
given below: 
 
H0: π T ≥ 21%   
 
H1: π T  <  21%  , where 
πT is the expected proportion of subjects undergoing AAA repair with the Ovation 
Abdominal Stent Graft System who experience a major adverse event at 30 days. The target 
performance goal rate of 21% is that based on the 11% rate (plu s 10% ”non-inferiority” 
margin) of major adverse events at 30 days  reported for the Medtronic Talent device 
(reported in the Medtronic Talent Summary of Safety and Effectiveness Data 2008). 
 
10.1.2  Primary Effectiveness Endpoint and Hy pothesis:  Treatment Success at 12 
Months 
Treatment success is the primary effectiveness endpoint for the study.  The proportion of 
subjects who are treatment succ esses at 12 months is the rate  of interest.  The null and 
alternative hypotheses are as follows: 
 
H0: π  ≤ 80%   
 
H1: π  >80%, where 
 
π is the expected rate of treatment success.  The Ovation Abdominal Stent Graft is 
considered to be effective if this study’s result verifies that the lower limit of the one-sided 95% confidence interval for π  is above 80%. 
10.2 Statistical Sample Size Justifications for the Primary Study Phase  
Should the rate of major adverse events be 11%, n=150 primary study subjects would provide 
96% power to test the primary safety hypothesi s at the one-sided 5%  significance level. 
 
It is anticipated that attriti on through the 12 month visit may be  approximately 15%.  Hence 150 
primary study subjects less 15% attrition would yield approximately 130 subjects with data 
available to assess the primary effectiveness endpoint at 12 m onths. Should the rate for the 
primary effectiveness composite endpoint e qual 88.2%, then 130 subjec ts would provide 80% 
power to test the primary effec tiveness hypothesis at the one-sided 0.05 alpha level. Sample size 
calculations were performed using the nor mal approximation in nQuery Advisor 6.02. 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 33 of 65 10.3  Statistical Methods for Primary Endpoints 
10.3.1  Primary Safety Endpoint: Major Adverse Events: 
Let n be the sample size and z 1-α denote the upper (1- α) quantile of the standard normal 
distribution.  If the upper limit of  the one-sided confidence interval  for the true rate of Major 
Adverse Events is less than 21%, then the null hypothesis for safety will be rejected in favor 
of the alternative hypothesis.  Therefore, the primary safe ty endpoint will be considered met 
if the upper bound of the 95% confidence interval  for the measured value is less than the 
performance goal (21%), based on the major adverse event rate.  An accurate estimate of the 
upper limit of a binomial proportion is presen ted by Agresti and Coull (Agresti 1998).1 The 
Agresti-Coull upper limit of a one-sided 95% confidence interval for the true rate of major 
adverse events is estimated by Formula 1, where 
 
Formula 1: 
 
) ( 2) 1 ( 4 ) 2 (
2
05 . 02
05 . 0 05 . 02
05 . 0
Z np pn Z Z Z npU+− + + +=    , where 
 p is the observed rate of Major Adverse Events and Z
u is the upper u-th 
percentile of the standard normal distribution. Hence Z .05 = 1.645.  
 
10.3.2  Primary Efficacy Endpoint: Treatment Success 
Let n be the sample size and z 1-α denote the upper (1- α) quantile of the standard normal 
distribution.  If the lower limit of the one-sided confidence interval for the true rate for 
treatment success is greater than 80%, then the null hypothesis defined in Section 10.1.2 will 
be rejected in favor of the a lternative hypothesis.  Using the sa me approach to calculate the 
confidence interval as used for the primary safety endpoint, the corresponding formula for 
the lower limit of the confidence interval is: 
 
Formula 2: 
 
) ( 2) 1 ( 4 ) 2 (
2
05 . 02
05 . 0 05 . 02
05 . 0
Z np pn Z Z Z npL+− + − +=    , where 
 
p is the observed rate of treatment success and Z u is the upper u-th percentile of the standard 
normal distribution. Hence Z .05 = 1.645.   
10.4 Secondary Statistical Endpoints 
No hypothesis testing will be performed for secondary endpoints. 
 10.4.1  Secondary Safety Endpoints 
Rates for all-cause mortality, AAA related mortality, major adverse events, AAA rupture, 
and surgical conversion will all be calculated at 30 days and 12 months .  The Kaplan-Meier 
estimates will be presented w ith 95% confidence intervals. 
   
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 34 of 65 10.4.2  Assessment of Clinical Utility 
 
Estimation of Mean Volume of Blood Loss 
For each subject, the amount of blood loss is the outcome variable.  The mean and standard 
deviation of blood loss values and 95% c onfidence intervals will be provided. 
 
Estimation of Mean Duration of Procedure, Overall Hospital Stay  
The objective is to estimate mean duration of procedure (minutes), mean time from hospital 
admission to discharge (days) and duration of an esthesia (minutes).   For each outcome the 
mean, median, standard deviation and 95% confidence interval will be provided.  
 
Anesthesia Type 
The objective is to estimate the rate of general anesthesia use. 
 
Vascular Access Type 
The objective is to assess the rate of femoral vs. percutaneous access used.  The rates will be 
presented as a percent with 95% confidence interval.  
10.4.3  Effectiveness 
All secondary effectiveness endpoints are categor ical in nature.  Tech nical success is only 
measured peri-operatively and will be presented as a percent with 95% confidence interval.  All the remaining effectiveness endpoints will be presented by visit, as percents with 95% 
confidence intervals. Endoleak  will be reported by type. 
10.5 Assumption Verification 
Visual inspection and statistica l tests will be used to determine if the study variables are 
consistent with the assumptions of  statistical tests proposed.  For continuous variables, test of 
normality will be done by Shapiro-Wilks test or equivalent. 
10.6 Study Retention and Handling of Missing Data 
Every effort will be made to co llect all data points in  the study. The sponsor plans to minimize 
the amount of missing data by appropriate manageme nt of the prospective clinical tr ial, proper 
screening of study subjects, and training of participating inve stigators, monitors and study 
coordinators.  Primary analyses will  be performed on an intent-to-treat basis.  All partial data that 
is available on subjects who drop out during the course of the study will be included.    
 In order to evaluate the effect of missing data on the primary out comes a sensitivity analysis will 
be performed.  The sensitivity analysis will include evaluating the primary outcomes using a 
best-case scenario (assuming missing data for the subjects are successes) a worse-case analysis 
(assuming all missing data for the subjects are failu res), and a tipping point analysis as described 
by Yan 2009.
2  A multiple imputation analysis will also be performed using logistic regression to 
further evaluate the effect of missing data on the primary outcome (Little 2001).3 
10.7 Poolability 
Data will be pooled from multiple study sites for th is analysis.  The justification for pooling is 
made on a clinical basis (Meinert, 1986).4  This study will be conducte d such that: 1) the same 
protocol will be used at each site; 2) site  investigators and pers onnel will receive uniform 
training; and 3) central data management and monitoring will be  applied with equal rigor at all 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 35 of 65 sites.  The diversity of hospital and clinical prac tice settings will add to the scientific validity and 
generalizability of the findings .  Rates for the primary efficacy and safety endpoints will also 
be reported by clinical centers. 
10.8 Subject Populations for Analysis 
Primary analysis will be performed on an intent-t o-treat basis.  The in tent to treat group will 
include all subjects in which the delivery sy stem is inserted in to the access vessels. 
10.9 Detailed Statistical Analysis Plan 
Prior to database lock a detailed statistical anal ysis plan will be written to provide a detailed 
description of the statistical analys is to be used in the final analys is.  This plan will incorporate 
lists of relevant variables to be included in multiple imputations analysis and will incorporate any 
protocol changes that w ould affect the analysis. 
10.10 Statistical References 
1. Agresti, A and Coull, B A (1998). Approximate is better than “exact” for interval 
estimation of bionomial pr oportions.  The American Statistician, 52:119-126. 
2. Yan, Xu, Lee, Shiowjen and Li, Ning (2009).  Missing Data Handling Methods in 
Medical Device Clinical Trials.  Journa l of Biopharmaceutical Statistics, 19: 6, 
1085-1098. 
3. Little, R. and D Rubin (2001).  Statistical  Analysis with Missing Data.  John Wilen 
and Sons, New York. 
4. Meinert, C. (1986). Clinical Trials: Design, Conduct, and Analysis.  Oxford 
University Press, New York. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 36 of 65 11.0  RISK ANALYSIS 
Treatment of an AAA with both e ndovascular and open surgical repair poses significant inherent 
risks to the subject.  The mortality risk of open surgical repair of an AAA is greater for those 
subjects with significant surgical risk factors, such as age and comorbidities (e.g., cardiac, renal 
and pulmonary).1   
 
Endovascular treatment of a AAA has been shown to be an effective, less i nvasive procedure that 
may result in reduced early mortality and fact ors related to morbidities, reduced time for 
anesthesia, need for blood products, shorter hospital stays and recovery  time, as well as 
improved quality of life in the early postoperative period.   
 Risks to subjects are minimized initially by including those patients that are considered to be suitable candidates for open surgical repair and by selecting qualified inve stigators/institutions 
with endovascular experience to participate in the study.  In order for patients to participate in this study, they must agree to adhere to a stri ct follow-up schedule to co ntinuously monitor their 
long term safety.   The risks associated with the use of this study device are no t currently known.  Although the 
adverse events associated with the use of the Ovation Abdominal Stent Graft System may be less than for standard open surgical repair, inherent risks exist, as with ma ny medical procedures.  
However, risks that have been associated with repa ir of AAAs with this type of device in clinical 
trials or that are currently marketed include, but may not be limited to: 
•
 Cardiac events such as congestive heart failure (CHF), vol ume overload, arrhythmias, 
myocardial infarction (MI), chest discomfo rt or angina, eleva tions in creatinine 
phosphokinase (CPK), hypotension 
• Pulmonary events such as pulmonary insufficiency, pneumonia, respiratory 
depression or failure, pulmonary edema, pulmonary embolism 
• Cerebral events such as cerebrovascular  accident (hemorrhagic or embolic), 
reversible ischemic neurologic deficit, transient ischemic attacks (TIA) 
• Acute and chronic renal insufficiency or failure, renal microembolism 
• Operative and post–operative bleeding disorders, hemorrhage and coagulopathy 
• Insertion and other vascular access site comp lications such as infection, bleeding, 
delayed healing, hematoma, dehiscence, seroma, nerve injury/damage, neuropathy, neuralgia, vasovagal response 
•
 Vascular injury including damage to bl ood vessels and surrounding tissues, vessel 
dissection, perforation, pla que dissection, collateral vessel occlusion, tissue loss, 
arterial fistula, limb loss, gangrenous dis ease, worsened or new onset claudication, 
edema 
• Neurological complications, such as paralysi s (temporary or permanent),  paraplegia, 
monoplegia, paresis, spinal cord ischemia, hemiplegia, bowel or bladder incontinence 
• Multi-system organ failure 
• Embolic and thrombotic events such as deep vein thrombosis , thromboembolism, 
microembolism, thrombophlebitis, phlebothrombosis, pulmonary embolism, air 
embolism 
• Gastrointestinal events such as ischemia, paralytic or adynamic ileus, obstruction, 
fistulas 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 37 of 65 • Impotence, erectile dysfunction 
• Radiation injury, late malignancy 
• Allergic reaction, such as flushing, na usea, vomiting, itching, hives, and/or  
anaphylactoid response to device materials (including polytetrafluorethylene [PTFE], 
PEG-based polymers, fluorinated ethylene pr opylene [FEP] or nitinol) and/or x–ray 
contrast dye  
• Generalized inflammatory response that may be associated with elevated levels of 
systemic mediators of inflammation, elevated temperature 
• General discomfort related to the procedure or tests, sore throat, pain 
• Infection–urinary tract, systemic or localized, sepsis, endograft 
• Device events such as endograft occlusion, migration, dislodgement, endoleak, and/or 
stent fracture 
• Branch vessel occlusion 
• Renal artery occlusion 
• Aneurysm rupture 
• Conversion to open surgical repair 
• Death 
 Potential benefits of the Ova tion Abdominal Stent Graft System  compared to open surgical 
aneurysm repair may include, but are not limited to: 
 Not having open surgery; 
 Less time under general anesthesia  and/or the ability to use other forms of anesthesia that 
do not require mechan ical ventilation; 
 Reduction of complications; and 
 Reduction in hospitalizati on and recovery time. 
 Potential benefits of the Ovati on Abdominal Stent Graft System co mpared to other commercially 
available endovascular AAA re pair devices may include, but are not limited to: 
 More robust seal between the graf t and aorta, possibly  reducing the risk that the graft will 
develop Type I or III endoleak s or migrate over time and; 
 Lower risk of injury to the access vessels due to the low profile and mo re flexible delivery 
system compared to the comm ercially available devices. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 38 of 65 12.0  STUDY RESPONSIBILITIES 
12.1  Responsibilities of Sponsor 
Sponsors are responsible for se lecting qualified investigators and providing them with the 
information needed to properly c onduct the investigation, ensure proper monitoring, IRB review 
and approval are obtained, submitting IDE application to the FDA and ensuring that reviewing 
IRBs and FDA are promptly informed of si gnificant new information about the study. 
The sponsor, the FDA, or other re gulatory bodies with responsibilities similar to FDA for clinical 
sites outside the United States, retain the ri ght to terminate the st udy and remove all study 
materials from the investigational site at any time.  Specific instances, which may precipitate study termination, are: 
• Unsatisfactory subject enrollment with regard to quality and quantity. 
• Deviations from protocol, without prior approval from the sponsor. 
• Inaccurate, incomplete, and/or untimely data recording on a recurrent basis. 
• The incidence and/or severity of adverse expe riences in this or ot her studies indicating a 
potential health hazard caused by the device. 
12.2  FDA and IRB approval 
A sponsor shall not begin an investigation un til an IRB and FDA have both approved the IDE 
12.3  Selection of Investigators 
A sponsor shall select investigators qualified by training and experience to investigate the device. 
12.4  Selection of Monitors 
A sponsor shall select monitors qualified by training and experience to monitor the study in accordance with applicable FDA regulations. 
12.5  Accountability and Control of Device 
Sponsor shall ship inves tigational devices only to qualified investigators part icipating in the 
study.  The investigator shall maintain adequate  records of the receipt and disposition of all 
investigational devices.  The investigator shall return any unused devices to sponsor with a 
completed device disposition record.  The disposition record shall include:  the devices being 
returned and the method of return.  Devices shall be maintained  in a secure, limited–access 
storage area.   
12.6  Obtaining agreements 
A sponsor shall obtain a signed agreement from each  participating investigator which includes a 
Curriculum Vitae (CV) with releva nt experience, as well as an e xplanation of any research that 
was terminated. 
12.7  Informing Investigators 
A sponsor shall supply all investig ators with copies of the inves tigational plan and inform them 
of any new relevant safety information obtained during the course of this investigation. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 39 of 65 12.8  Monitoring Investigations 
Monitoring visits to the clinical sites will be ma de periodically during the study, to ensure that 
the clinical trial is be ing conducted in strict accordance wi th the protocol/ame ndment(s) and in 
compliance with Good Clinical Practice as defined by the Food and Drug Administration (FDA) 
and by ICH Harmonized Tripartite Guidelines, and that the clinical data can be validated against 
source documentation at the investig ative site.  Original source doc uments will be reviewed for 
verification of data recorded on the eCRF s and in the electronic database.  The 
Investigator/institution guarantees direct access to original source documents by TriVascular personnel, their designees, and appr opriate regulatory  authorities.  In the event that  the original 
medical record cannot be obtai ned for a subject that is s een by a non-study physician at a non-
study institution, photocopies of the original source documents must be made available for 
review.  Sponsors may discontinue shipments of devices and terminate the investigat or’s participation if 
determination has been made that the investigat or is not compliant with the signed agreement, 
the protocol, conditions imposed by the reviewing IRB, or the applicable  FDA regulations.   
12.9  Responsibilities of Investigators 
An investigator is responsible  for ensuring that the study is conducted in accordance with the 
signed agreement, the protocol, IRB and FDA regul ations and requirements. An investigator is 
also responsible for adhering to regulations associated with obtaining informed consent.  An investigator shall permit an in vestigational device to be used  only with subjects under the 
investigator’s supervision.  An investigator shall disclose to the sponsor accurate financial information required per 21 CFR, Part 54.  Investigator shall return unused devices to the 
sponsor, or dispose of devi ce as directed by sponsor. 
 
TriVascular Clinical Field Specialists will be in attendance during the implant of the study device to 
provide technical assistance to the investigators. These field specialists w ill be supervised by the 
investigator to eliminate the potential for biasing the outcome of studies, affecting the quality of 
research data, and/or compromising the rights and welfare of human subjects.  
 
Additionally, investigators are responsible for maintaining accu rate, complete and current 
records pertaining to correspondence, device acc ountability, each subject case history, including 
evidence of informed consent.  Reports of an y IRB withdrawal, unanticipated adverse device 
effects, deviations from the protocol, use of a device without obtaining subj ect consent, as well 
as progress reports to IRB (annually  at minimum) are also the res ponsibility of the investigator. 
12.10 Source Documentation 
Investigators are responsible for maintaining information in the study subjects’ medical records 
that corroborate data entered into the CRF.  The following documents will be maintained and made available as required by the sponsor’s desi gnated monitors and/or regulatory inspectors: 
 1. Medical and surgical histor y/physical condition of the subject  prior to part icipation in 
the study in order to verify  protocol entry criteria. 
2. Dated and signed notes in the subjects’ medical record that verify that informed 
consent was obtained. 
3.  Dated and signed notes from each subject visit with reference to the data collected. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 40 of 65 4.  Description of device implantation proce dure (date, time, medications, AEs, duration 
of procedure, etc) 
5.  Notations on abnormal lab results and thei r resolution. 
6.  Dated printouts of diagnostic repo rts of assessments (CT, X-ray, etc) 
7.  Adverse event reporti ng and follow-up of the AE. 
8.  Subjects condition upon completion of or withdrawal from the study. 
12.11 Maintaining Records 
TriVascular will maintain hard or electronic copi es of correspondence, da ta, shipment of devices, 
adverse device effects, and other records related to the clinical trial.  All Core Labs and clinical 
sites will maintain study records for tw o (2) years after study completion.   
It is the responsib ility of the inves tigator and the study staff to maintain a comprehensive and 
centralized filing system of all relevant study docum entation which may include: 
• Subject Files – which substant iate the data entered in the electronic Case Report Forms 
for all required tests and procedures. 
• Subject Identification Log – a list correlating all subject names, appropriate identifying 
information, etc., to the TriVascular assigned subject number. 
• Screening Log – which should reflect the reason a ny subject was screened for the study 
and found to be ineligible. 
• Monitoring Visit Log – which lists dates of monitor/sponsor visits. 
• IRB Correspondence – includes approval letter( s), and any adverse event reporting or 
other correspondence with the IRB. 
• Sponsor Correspondence –letters, e-mails, or fa xes sent to the inve stigator or study 
coordinator at the i nvestigational site. 
• Site Correspondence – letters or  fax sent to the sponsor fr om the investigator or study 
coordinator at that site. 
• Signed Informed Consent for each subject 
• Informed Consent Log – lists version of c onsent(s) signed by each subject screened and 
enrolled into the study 
• Device Inventory Log – includes a list of any devices received by the site, used in a case 
and/or returned to the sponsor. 
All Study Documentation pertaining to the conduct of the st udy must be kept on file by the 
investigator for a minimum of two (2) years af ter being notified by the sponsor of either PMA 
approval or discontinuation of the Sponsor’s IDE. 
In compliance with current regulat ory guidelines regarding the monitoring of clinical studies, it 
is requested that the investigat or permit the study monitor to review and duplicate information in 
the subject’s medical record that is directly related to the study.  This information may include  
relevant study documentation, including the subject ’s medical history, to verify eligibility, 
laboratory test results to verify transcription accuracy, x–ra y reports, admission and discharge 
summaries for hospital or outpatient admissions o ccurring while the subject is participating in 
the study, charges and billing, and autopsy re ports for deaths occurring during the study (if 
available). 
As part of the required content of informed consent, the subject must be informed that his/her 
medical record will be reviewed and, possibl y, duplicated by the sponsor, or the sponsor’s 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 41 of 65 authorized representative or government regulat ory authorities.  Shoul d access to the medical 
record require a separate waiver or authorization, it is  the investigator’s re sponsibility to obtain 
such permission from the subject in writing before the patient subj ect is entered into the study. 
12.12 Study Deviations  
A study deviation is defined as an event where th e investigator or site personnel did not conduct 
the study according to the investigational plan, protocol or the investigator agreement.  
Investigators shall be required to obtain prio r approval from TriVascular clinical study 
management before initiating deviations from th e protocol, except where n ecessary to protect the 
life or physical well being of a subject in an emergency.  Such  approval shall be documented in 
writing and maintained in clinical study management  and investigator files.  Prior approval is 
generally not expected in situ ations where unforeseen circumst ances are beyond the investigators 
control (e.g., missed visits or tests); however, the event is still considered a deviation and will be 
collected on the Deviation eCRF .  Investigators are responsibl e for reporting deviations in 
accordance with the revi ewing IRB policies. 
 FDA regulations require that investigators maintain accurate, complete, and current records, including documents showing the dates of and reasons for each deviation from the protocol.  The following information outlines requirements for the reporting of protocol deviations: 
 
Type of Deviation Investigator to notify: Reporting timeline 
Emergency procedures to protect the life or physical well-being of a subject  TriVascular and reviewing IRB Within 5 days of event 
Changes in or Deviations from the investigational plan  Prior approval from: 
TriVascular, IRB and FDA Prior to use 
Non-urgent protocol deviation TriVascular, IRB (if required) Upon CRF completion.  Deviations directly related to the study endpoints will be summarized and submitted in an annual report to the FDA 
12.13 Termination of Study 
The sponsor or the FDA retains the right to terminate the study and remove all study materials 
from the investigational site at any time.  Specific instan ces, which may precipitate study 
termination, are: 
1. Unsatisfactory subject enrollment with regard to quality and quantity. 
2. Deviations from protocol, without prior approval from the sponsor. 
3. Inaccurate, incomplete, and/or untimely data recording on a recurrent basis. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 42 of 65 4. The incidence and/or severity of adverse expe riences in this or other studies indicating a 
potential health hazard caused by the device. 
5. Submission of fraudulent data. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 43 of 65 13.0 STUDY COMMITTEES 
13.1  Data Safety Monitoring 
A Data Safety & Monitoring Board (DSMB) committ ee shall be used to re view the progress of 
the clinical study.  The committee will be responsible for reviewing the data associated with the 
device and the subjects.  It will provide independent recommendations to the sponsor based on its review of the data and input from the Clin ical Events Committee (CEC).  The DSMB shall 
meet annually, at a minimum. 
13.2  Clinical Events Committee 
The Clinical Events Committee (CEC) shall be us ed to review and adj udicate all device related 
adverse events (AE) and all serious adverse events (SAE) regardless of the relatedness to the device.  The CEC shall also determine which adverse events are considered Major Adverse 
Events (MAE) for evaluation of the primary (30 da ys) and secondary (1 year) safety endpoints.  
The committee shall consist of at least three (3) physicians representing multiple specialties 
familiar with abdominal aortic aneurysm repair .  The CEC will provide their review to the 
DSMB and shall meet annually, at a minimum. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 44 of 65 14.0 TRAINING 
TriVascular will provide techni cal training and support.  Physician training may involve a 
didactic review of the research team’s study resp onsibilities and hands on device implantation in 
a simulated anatomic model.  The emphasis duri ng physician training will  include: protocol and 
study compliance, compliance with a pplicable regulations, subject se lection criteria, sizing of the 
stent graft, mechanics of the Ovation Abdominal Stent Graft System  and its deployment, as well 
as the essential ancillary equipment necessary to  perform the implant pr ocedure with the device.   
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 45 of 65 15.0 INFORMED CONSENT  
All subjects must provide written informed cons ent in accordance with the reviewing IRB policy 
and procedures.  The process of obtaining informed  consent must be documented in the subject’s 
medical record.  If changes to the TriVascular in formed consent template are to be made, these 
changes must be submitted and approved by TriVascular prior to IRB submission.  Each clinical 
site must provide TriVascular with a copy of the IRB approval letter, which states the study 
name, protocol revision being approved as well as the approval date.  A copy of the approved 
informed consent must also be submitted to TriVas cular.  A template for the Informed Consent is 
provided in Appendix V: Informed Consent Template . Clinical sites ar e responsible for 
maintaining annual approval (as appropriate) a nd submitting the annual approval letters to 
TriVascular.  
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 46 of 65 APPENDIX I: REFERENCES 
1. Hallin, A., Bergqvist, Holmberg, L.  Literatu re Review of Surgical Management of 
Abdominal Aortic Aneurysm.  Eu r J Vasc Surgery 2001; 22:197-204. 
 
2. Guirguis, E. M., Barber, G. G., The Natura l History of Abdominal Aortic Aneurysms. 
Am J of Surgery 1990; 162:481-483 
 
3. Brewster, D. C., Cronenwett, J. L., Hallett, J. W. Jr., Johnston, K.W., Krupski, W. C., 
Matsumura, J. S.  Guidelines for the Tr eatment of Abdominal Aortic Aneurysms. J 
Vascular Surgery 2003; 37:1106-1116 
 
4. Menard, M. T., Chew, D. K.W., Chan, R. K., Conte, M. S., Donaldson, M. C., Mannick, 
J. A., Whittemore, A. D., Belkin, M.  Outcome in Patients at high risk after open surgical repair of abdominal aortic aneurysm.  J Vascular Surgery 2003; 37:285-292. 
 
5.
 FDA Public Health Notification:  Updated Da ta on Mortality Associated with Medtronic 
AVE AneuRx® Stent Graft Sy stem.  December 17, 2003 
 
6. Matsumura, J. S., Brewster, D. C., Makaroun, M. S., Naftel, D. C. A multicenter controlled clinical trial of open versus e ndovascular treatment of abdominal aortic 
aneurysm.  J Vascular Surgery 2003; 37:262-271. 
 7.
 Buth, J., van Marrewijk, C. J., Harris, P. L., Hop,  W. C. J., Riambau, V., Laheij, R. J. F.  
Outcome of endovascular abdominal aortic an eurysm repair in patients with conditions 
considered unfit for an open procedure:  A Report on the EUROSTAR experience. J 
Vascular Surgery 2002; 35: 
 
8. Lavori, P.W., Dawson, D., Shera, D. “A Multiple Imputation Strategy for Clinical Trials 
with Truncation of Patient Data.” Sta tistics in Medicine, Vol 14, (1995):1913-1925.]
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 47 of 65 APPENDIX II: REFERENCES R ELATED TO COMPLICATIONS 
 
1) AbuRahma, A. F., Robinson, P. A., Boland, J.  P., Lucente, F. C., Stuart, S. P., Neuman, 
S. S., Hall, M. D., Hoak, B. A..  Elective re section of 332 abdominal aortic aneurysms in 
a southern West Virginia community during a recent 5-year period.  Surg 1991; 109 (3) 
Part I: 244-251.  
2) Bernstein, E. F., Dilley, R. B., Randolph II I, H. F.  The improving long-term outlook for 
patients over 70 years of age with abdominal aortic aneurysms.  Ann Surg 1988; 207 (3): 
318-322.  
3) Brewster, D. C., Geller, S. C., Kaufman, J. A ., Cambria, R. P., Gertler, J. P., LaMuraglia 
G. M., Atamian S., Abbott W. M.  Initial experience with endovascular aneurysm repair: 
Comparison of early results w ith outcome of conventional op en repair.  J Vasc Surg 
1998; 27 (6): 992-1005.  
4) Buth, J., Laheij, R. J. F. Early complicati ons and endoleaks after endovascular abdominal 
aortic aneurysm repair: Report of a multicenter study.  J Vasc  Surg 2000; 31 (1), Part I: 
134-146. 
5) Chuter, T. A., Risberg, B., Hopkinson, B. R ., Wendt, G., Scott, A. P., Walker, P. J., 
Viscomi, S., White, G.  Clinical experien ce with a bifurcated endovascular graft for 
abdominal aortic aneurysm repair.  J Vasc Surg 1996; 24 (4): 655-666.  
6) Diehl, J. T., Cali, R. F., Hertzer, N. R., Beve n, E. G.  Complications of abdominal aortic 
reconstruction: An analysis of perioperative risk factors in 557 pa tients.  Ann Surg 1983; 
197 (1): 49-56.  
7) May, J., White, G. H., Yu, W., Ly, C. N., Wa ugh, R., Stephen, M. S., Arulchelvam, M., 
Harris, J. P.  Concurrent comparison of endol uminal versus open repair in the treatment 
of abdominal aortic aneurysms: Analysis of  303 patients by life table method.  J Vasc 
Surg 1998; 27 (2): 213-221.  
8) May, J., White, G., Waugh, R., Stephen, M. S., Chaufour, X., Yu, W., Harris, J. P.  
Adverse events after endoluminal repair of  abdominal aortic aneurysms: A comparison 
during two successive periods of time.  J Vasc Surg 1999; 29 (1): 32-39.  
9) Mialhe, C., Amicabile, C., Becquemin, J.  Endovascular treatment of infrarenal 
abdominal aneurysms by the Stentor system: Pr eliminary results of 79 cases.  J Vasc Surg 
1997; 26 (2): 199-209.  
10) Perry, M. O., Calcagno, D.  Abdominal aortic aneurysm surgery: The basic evaluation of risk.  Ann Surg 1998; 208 (6): 738-742.  
11)
 Richardson, J. D., Main, K. A.  Repair of  abdominal aortic aneurysms: A statewide 
experience.  Arch Surg 1991; 126 (5): 614-616.  
12) Stelter,W., Umscheid, T., Ziegler, P.  Thr ee-year experience with  modular Stent graft 
devices for endovascular AAA treatment.  J Endovasc Surg 1997; 4: 362-369. 
13) Zarins, C. K., White, R. A., Schwarten, D., Kinney, E., Dietrich, E. B., Hodgson K. J., 
Fogarty, T.J.  AneuRx Stent graft versus open surgical repair of abdominal aortic 
aneurysms: Multicenter prospect ive clinical trial.  J Va sc Surg 1999; 29 (2): 292-308. 
14) Nayak, K. R., White, A. A., Cavendish, J. J, Barker, C. M., Kandzari, D. E. Anaphylactiod Reactions to Radiocontrast Agents:  Prevention and Treatment in the Cardiac Catheterization Laboratory.  J Invasive Card iol 2009; 21:548-551. 
15)
 Canter, L. M. Anaphylactiod Reactions to Radiocontrast Media. Allergy and Asthma 
Proc 2005; 26:199-203. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 48 of 65 16) Honari, G., Ellis, S. G., Wilkoff, B. L., Aroni ca, M. A., Svensson, L. G., Taylor, J. S. 
Hypersensitivity reactions a ssociated with endovascular devices. Contact Dermatitis 
2008; 59:7-22. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 49 of 65 APPENDIX III: ASA CLAS SIFICATION SYSTEM 
 
American Society of Anesthesiologists Classification System 
 
The American Society of Anesthesiologists (ASA ) presents a graded scale assessing a patient’s 
risk of undergoing anesthesia.  Th e scale represents the significan ce of the patient’s underlying 
illnesses prior to anesthesia. 
 The following provides a description of the four grades of the ASA scale: 
 
ASA I 
Healthy individual without any systemic disease , undergoing elective surgery.  Patient not at 
extremes of age.  (Note: Age is sometimes ignored as a ffecting operative risk ; however, patients 
at either extreme of age are though t to represent increased risk.)  Some examples are a fit man 
with an inguinal hernia, and a fibroid uterus in an otherwise healthy woman. 
 
ASA II 
Individual with one system, well -controlled disease.  Disease does not affect daily activities.  
Other anesthetic risk factors, including mild obesity, alcoholism, and smoking can be 
incorporated here.  Examples include non-limiting or  only slightly limiting organic heart disease, 
essential hypertension, anemia, or mild diabetes.  
ASA III 
Individual with multiple system disease or well controlled major system disease .  Disease does 
limit daily activities.  No immediate danger of death from any individua l disease.  Examples 
include severe organic heart dise ase, severe diabetes with vascular complications, moderate to 
severe degrees of pulmonary insufficiency, angina or healed m yocardial infarction. 
 
ASA IV  
Individual in imminent danger of d eath.  Surgery is viewed to be last resort at salvaging life.  
Individual not expected to live through the next 24 hours.  In some cases, the individual may be 
healthy prior to catastrophic event that led to the current medical condition.  Examples include 
ruptured abdominal aortic aneurysm with prof ound shock, major cerebral trauma with rapidly 
increasing intracranial pressu re, massive pulmonary embolus. 
 
Reference: Composite from different editions  of:  Sabiston, DC, Textbook of Surgery.  
Philadelphia: W.B. Saunders Company  
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 50 of 65 APPENDIX IV: SCHEDULE OF ACTIVITIES 
 
 
 
1X-ray images should include: AP, lateral, left oblique and right oblique views.  
2PT, PTT and INR are optional after Baseline. 
3Baseline med/surg history, physician exam/ABIs,  and laboratory assessments performed no more than 
one month prior to the implant/surgical proce dure. Serum pregnancy HCG required for females 
of child-bearing potential only. 
4Baseline contrast enhanced CT must be obtained within 6 months of anticipated treatment date. 
5Only the device will be assessed  at discharge as no CT is performed at that visit. 
 
 Procedure Baseline Treatment Discharge 1 Month 
Follow-Up 6 Month 
Follow-Up 12 Month Follow-Up  Annual  Follow-Up 
Medical/Surgical 
History X3       
Physical Exam   X3  X X X X X 
ABI X  X     
Spiral Contrast Enhanced CT X4   X X X X 
Abdominal X-ray1   X X X X X 
Laboratory Assessment (BUN, creatinine, PT, PTT, INR)
2 X3  X X X X X 
Adverse Event Assessment  X X X X X X 
Concomitant Medication 
Assessment 
(anticoagulants, antiplatelets, 
antibiotics only) X X X X X X X 
Device/aneurysm 
assessment based on 
imaging (endoleak, 
migration, integrity, patency)  X
5  X X X X 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 51 of 65 APPENDIX V: INFORMED CONSENT TEMPLATES 
 
DRAFT SCREENING INFORMED CONSENT 
 
Study Title:  A Pivotal Clinical Study to Evaluate  the Safety and Effectiveness of 
the Ovation Abdominal Stent Graft System 
 
Trial Number:   771-0006 
 
Researcher:    Investigator Name 
Site Name 
Site Address Site Address Investigator Telephone:   
Sponsor:   TriVascular, Inc. 
3910 Brickway Blvd. Santa Rosa, CA 95403 Telephone: +1 707.543.8811 
  
Patient Name:  _________________________   
  I, ___________________________________, an adult, voluntarily consent to release my medical records for screening evaluations for possi ble participation in a clinical research study 
sponsored by TriVascular, Inc. The TriVascular Pivotal Clinical Study is to  evaluate the Safety 
and Effectiveness of the Ovation Abdominal Sten t Graft System for the treatment of abdominal 
aortic aneurysms.  I understand that in order to determine my eligibility to pa rticipate in the study, medical 
information from my CT scans and/or x-rays wh ichever is deemed appropriate and available, 
will be evaluated by the study sponsor and an independent laboratory appointed by the study 
sponsor, who will read the scans/x-rays and take anatomical measurements.  I have been informed that my name may appear  on the films (x-rays) that will be sent to the 
sponsor. All personal information taken and record ed will be treated in strict confidence. I 
understand that my personal identity will not be used by the sponsor for any public disclosure. 
 I understand that my consent is for screening only and is not my  consent to participate in the 
study. I understand that the CT s cans or x-rays are part of the standard evaluation for abdominal 
aortic aneurysms and are not taken sp ecifically for research study purposes. 
 I hereby authorize my physician to release the information from my  CT scans or x-rays to the 
study sponsor and the independent co re laboratory to evaluate and determine my eligibility to 
participate in research. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 52 of 65  
________________________________________________________________ 
Participant’s (or representative) printed full name  
 
_______________________________________  __ __ / __ __ / __ __ __ __ Participant’s (or representative) signature Date (dd/mm/yyyy) (written by the participant 
or his/her representative) 
 ________________________________________________________________ 
Impartial witness (full name) (Witness signature required  only in the event the patient cannot read and/or 
sign the Informed Consent; for instance, if the patient is illiterate or blind) 
 _______________________________________  _______________________ Signature of the impartial witness (if required)   Date (dd/mm/yyyy) (written by the witness) 
 
 
____________________________________ __ __ / __ __ / __ __ __ __ 
Principal Investigator or Author ized Designee  Date (dd/mm/yyyy) 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 53 of 65 DRAFT INFORMED CONSENT 
 
Study Title:  A Pivotal Clinical Study to Evaluate  the Safety and Effectiveness of 
the Ovation Abdominal Stent Graft System 
 
Trial Number:   771-0006  
 
Researcher:    Investigator Name 
Site Name 
Site Address Site Address Investigator Telephone:   
Sponsor:   TriVascular, Inc. 
3910 Brickway Blvd. Santa Rosa, CA 95403 Telephone: +1 707.543.8620 
  
Patient Name:  _________________________ Patient #:   ______________ 
 
WHAT IS INFORMED CONSENT? 
When researchers ask for your consent, they are asking for your voluntary agreement to take part 
in a test, procedure, or clini cal research trial.  Informed consent means more than signing a 
printed consent form.  To be informed, you need to  know about benefits and risks of the clinical 
research trial and how it may a ffect you, your family, and society.  The following document is 
called a consent form and describes the clinical research trial and what your role will be as a 
study participant. 
 
This consent form may contain words that you  do not understand.  Please ask the doctor in 
charge of the study, your own doctor, or the staff involved with the clinical research trial to 
explain any words that you do not understand before signing this form.  You may also contact 
the organizations listed in the Section below entitled “Persons To Contact For Research 
Questions” for any questions you may have regardi ng this research study.  You will be given a 
copy of the signed consent form. 
PURPOSE OF THE STUDY 
You have been asked to consider participating in a clinical research study designed to determine the safety and effectiveness of the Ovation Abdominal Stent Graft System, an investigational device used in the treatment of abdominal aortic aneurysms (AAA).  This study will be conducted at approximately 40 clinical sites and will enroll up to 150 subjects during the initial study phase with an additiona l 100 subjects enrolled during the continued access phase. 
 An abdominal aortic aneurysm is a bulge in the ao rta (the main artery leaving the heart) caused 
by a weakening in the artery wall.  If left untreat ed, this bulge may continue to grow larger and 
ultimately rupture (break open), resulting in serious  internal bleeding.  The information collected 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 54 of 65 from this study will be used to evaluate how well patients do when treated with the Ovation 
Abdominal Stent Graft System both immediately af ter surgery and over a long period of time.  If 
you decide to participate in this study, your medical condition will be carefully monitored. 
 
Treatment of your AAA with the Ovation Abdomi nal Stent Graft System involves the placement 
of specially designed grafts (fabri c tubes) in your aorta.   The main graft looks  like a pair of pants 
with very short legs.  The top of the pants w ill be placed in your aorta.  Then, two or more 
smaller grafts are used to extend from the main graft into your iliac arteries (the main arteries supplying blood to your abdomen and legs) to form the legs of the pair of pants.  Each graft is 
enclosed in a small catheter (a long, flexible tube) th at is inserted  into your aorta through the 
femoral artery in your groin (top of  your leg).  The grafts are then placed in the correct position 
in your aorta by releasing them from the catheters.  Once the gr afts are attached inside your 
aorta, they will reinforce the area of your aorta that is w eakened and bulging from your 
aneurysm.  This procedure is called an endovas cular aneurysm repair because the grafts are 
delivered through your blood vessels.    In standard surgical aneurysm repair, the surg eon makes a large incision in your abdomen and 
actually cuts into your aorta and sews a graft in place.  There are other endovascular AAA repair 
devices that are approved for use by the F ood and Drug Administratio n (FDA) in the United 
States (U.S.).  You have the choice of having your treatment with the investigational Ovation Abdominal Stent Graft System or with any other AAA repair device which is already FDA 
approved.  You also have the choice of having your treatment with standard surgery or choosing 
to have no treatment for your aneurysm.  
EXPLANATION OF PROCEDURES 
In preparation for this research study, you will  have a physical examina tion by the study doctor, 
an evaluation of your medical hi story and any risk factors, and a check of the blood pressures in 
your arms and legs.  You will also have appr oximately 2 tablespoons, or  30 milliliters, of blood 
drawn from a vein using a needle, so that tests of your kidney function and your body’s blood-clotting abilities can be performed.  If you are a female with child bearing potential, you will also 
have a blood pregnancy test perf ormed to make sure you are not pregnant. Since your doctor has 
already diagnosed your aneurysm, you may have al ready had a special x-ray, called a CT scan.  
If you have not had a CT scan, or if the CT s can information is not detailed enough to let your 
doctor evaluate your aneurysm, you will be required  to have a CT scan. These same tests would 
be done if you were scheduled to undergo standard  surgery to repair your  aneurysm or if you 
were going to have an endovascular  AAA repair using another device. 
 As the procedure begins, you will receive a drug in your hand or arm to help sedate you, or you 
might receive general anesthesia depending upon your particular circumstance.  Your surgeon 
will clean your skin and shave hair around the pl ace where the device will be inserted through a 
catheter (flexible tube) into your body.  Your surgeon will then make an incision (cut) into the 
skin in order to get access to the femoral artery in your groin (top of leg). Your surgeon will then 
thread a very thin wire into your artery to guide it to the aneurysm. Because you have no nerve 
endings inside your arteries, you will not feel th e wires or catheters as they move through your 
body. You may feel a slight pressure or a sens ation of mild tugging during this part of the 
procedure.   
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 55 of 65 The main catheter containing the fi rst piece of the graft will be advanced  through your femoral 
artery up to a level in the ao rta above the aneurysm, but belo w the arteries that go to your 
kidneys.  The graft will be released from the catheter and the catheter will be pulled away.  A 
special material will be inserted into tubes inside the wall of the main graf t to ensure it is tight 
against the artery wall.  Then, catheters are used to place the two or more smaller grafts into your 
iliac arteries to complete the procedure.  All the catheters will be removed leaving the graft in place inside your aorta.  The incisions in your gr oin arteries and in your skin will be closed by 
your doctor.  After the procedure has been completed and you have  had time to recover from the sedation, you 
will be kept in the hospital until your doctor al lows you to go home.  Prior to your discharge 
from the hospital, you will have physical examinations, the blood pr essure in your arms and legs 
will be checked, an X-Ray of your abdomen a nd you will have blood te sts that will require 
approximately 2 tablespoons, or 30 mill imeters, of blood to be drawn.  
FOLLOW-UP EVALUATIONS 
If you decide to participate in this research study, you will be required to return to your doctor 
for follow-up evaluations at one (1) month, six (6) months, and twelve (12 months) after the procedure, as well as every year thereafter  until five (5) years after the procedure. 
 At each of the follow-up visits, you will have  a physical exam, CT scan, X-Ray of your 
abdomen, and blood tests that will require approximately 2 tablespoo ns, or 30 millimeters, of 
blood to be drawn.  If you experience any probl ems with your grafts, your physician may ask to 
see you more frequently and a dditional tests may be done. 
 It is very important to complete these follow-up visits even if you are feeling well and not having 
any symptoms.  These visits are important for documenting how well the treatment has worked. 
It is also very important that  you contact your doctor if you have any symptoms that may be 
related to the treatment that you received so that your condition can be properly checked. 
ALTERNATIVE TREATMENTS 
Alternative procedures to repair your AAA incl ude standard surgical aneurysm repair and 
endovascular repair using a commercially available endovascular AAA repair device.  In 
standard surgical aneurysm repair, the surg eon makes a large incisi on in your abdomen and 
actually cuts into your aorta a nd sews a graft in place.  The procedure with a commercially 
available endovascular AAA repair device is very similar to  the procedure with the Ovation 
Abdominal Stent Graft System, by placing the device through your  groin (femoral) arteries. 
RISKS 
The risks associated with the use of this study device are no t currently known.  Although the 
adverse events associated with the use of the Ovation Abdominal Stent Graft may be less than for standard open surgical repair, inherent ri sks exist, as with many medical procedures.  
However, risks that have been associated with repa ir of AAAs with this type of device in clinical 
trials or that are currently marketed include, but may not be limited to: 
 hematoma (deep bruise) or lymphatic problems (i nfection) at the access sites in the groin;  
 damage to the iliac or femoral ar teries during devi ce deployment;  
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 56 of 65  fracture of the metallic components of the implant; 
 endoleak (leakage of blood around the graft in to the aneurysm sac a nd/or blood flow into 
the aneurysm sac from vessels  connected to the aorta); 
 continued enlargemen t of your aneurysm; 
 failure to deploy the graft resulting in the need to stop th e procedure and/ or convert to 
open surgical repair; 
 twisting of the implanted graft; 
 migration of the some or all of the device parts; 
 separation of im plant parts; 
 aortic occlusion (blockage or the blood flow in your aorta) from blood clots;  
 kinking or twisting of the graft and iliac artery occlusion (blockage of blood flow in the 
blood vessels that supply blood to  your legs) from blood clots,  kinking or twisting of the 
legs of the graft; and 
 allergic reaction to the device fi ll material, if injected into the bloodstream, as well as 
device materials. 
 
Complications common to all pa tients undergoing standard su rgical aneurysm repair or 
endovascular repair include, but  may not be limited to:  
 allergic reaction to x-ray contrast dye; 
 procedural bleeding; 
 post-procedure bleeding;  
 hematoma (deep bruise);  
 bleeding disorders;  
 respiratory failure;  
 pneumonia;  
 pulmonary embolism (blood clots in the lung);  
 myocardial infarction;  
 congestive hear t failure;  
 irregular heart beat requiring therapy;  
 kidney failure; w ound infection;  
 bowel complications such as pa ralysis of the bowel; blockage of the bowel; or decreased 
blood flow to the bowel tissue; 
 mild or severe blockage of blood flow to your legs or arms due to blood clots or damage 
to the blood vessels;  
 amputation;  
 stroke;  
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 57 of 65  impotence;  
 blood clots or infection in the graft; graft dila tation (stretching);  
 development of a hole between th e aorta and the intestines or the aorta and the vena cava 
(major blood vessel carryi ng blood to the heart);  
 separation of the wall s of the aorta;  
 a false aneurysm developing at th e fixation point of the graft; 
 re-operation (a dditional surgery); and  
 death.   
Your doctor will make every effort to minimize the risks and discomforts of the procedures.  
Most of the complications and discomforts liste d above can be treated with medications or 
surgery that can be given to you if your doctor f eels it is needed.  In the event of a serious 
complication or injury, it may be necessary to surgically remove the study de vice. In that case, 
TriVascular requests that the removed study devi ce be returned to them for examination. 
POTENTIAL BENEFITS 
Potential benefits of the Ova tion Abdominal Stent Graft System  compared to open surgical 
aneurysm repair may include, but are not limited to: 
 Not having open surgery; 
 Less time under general anesthesia  and/or the ability to use other forms of anesthesia that 
do not require mechan ical ventilation; 
 Reduction of complications; and 
 Reduction in hospitalizati on and recovery time. 
 
Potential benefits of the Ovati on Abdominal Stent Graft System co mpared to other commercially 
available endovascular AAA re pair devices may include, but are not limited to: 
 More robust seal between the graft and your aorta, possibly reducing the risk that the graft 
will develop leaks or move over time and; 
 Lower risk of injury to  the vessels in your legs because this cathe ter is smaller and more 
flexible than the commercially available devices. 
Any potential benefits cannot, however, be guaranteed. There may be no direct benefit to you from your participation in this  study, but it is hoped that th e information gained from your 
participation in this study may benefit others with a condition similar to yours. 
CONFIDENTIALITY 
The information obtained about you due to taking pa rt in this study will be kept confidential to 
the extent allowed by law.  Total confidentiali ty cannot be guaranteed. However, all medical 
records and research materials th at would identify you will be he ld confidential.  Your identity 
will remain confidential unless the law requires disclosure. By signing this consent, you grant 
permission for medical information about you obtained during this st udy to be made available to 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 58 of 65 authorized representatives of  the FDA and other government agencies. You also grant 
permission for this medical information to be made available to the following people: 
• TriVascular, the Sponsor—the manufacturer  of the Ovation A bdominal Stent Graft 
System and the company funding the Study, a nd its employees (e.g., Clinical Field 
Specialists who are in attendance during the pr ocedure to provide technical assistance to 
your physician) who are involved in the conduct of the study. 
• Employees of a Contract Research Organizatio n, a company contracted by TriVascular to 
supervise/validate the clinical information obtained in the Study.  
• The local Institutional Review Board (IRB). 
The results of this research study may be pub lished or used for teaching purposes; however, 
patients will not be identified by name in those publications or teaching materials.  You will be 
assigned a special study code th at will not reveal your name  or personal identity.   
 You will be asked to review and sign a special doc ument, along with this informed consent form, 
that describes the privacy law, Health Insurance Portability and Accountability Act (HIPAA), so that the researchers can use or disclose your protected health in formation for research purposes. 
RIGHT OF REFUSAL AND STUDY TERMINATION 
Your participation in this study is voluntary.  Your refusal to participate will not prejudice your 
future treatment or benefits.  You are free to st op participation in the st udy at any time without 
fear of penalty or loss of medical care. You w ill be asked to come in for a final study visit. 
 Your doctor may also terminate your participation in  this study, if in his or her medical judgment 
it is in your best interest not to continue.  You will be informed, if  important new findings 
develop during the study that may af fect your willingness to continue. 
COSTS OF TREATMENT AND STUDY PARTICIPATION 
You and/or your third party payer (Medicare or  other health insurance company) will be 
responsible for the costs of your treatment pr ocedures and follow-up examinations which are 
considered standard of care for endovascular AAA repair.  The cost of any test or examination 
which is not considered standard of care or reimbursable by your third party payer (insurance) 
will be covered by the study sponsor.   
PAYMENT FOR STUDY PARTICIPATION 
You will not be compensated or paid for your part icipation in this study.  Any reasonable costs 
you incur traveling to your phys ician for required follow-up visits will be reimbursed by the 
sponsor, TriVascular, Inc., if agreed to in advance of your visit.  Please contact ____________, 
the Research coordinato r for this study at __________________ <insert institution name>  to 
arrange for reimbursement. 
RESEARCH RELATED INJURIES 
If physical injury occurs that is  directly related to your involvement in this research, you will 
receive any medical treatm ent that is necessary to assist your  recovery from the injury.   The 
costs of medical care associated wi th injuries related to your participation in this study will be 
provided by the sponsor, TriV ascular, Inc, provided th at the injury is a direct  result of the use of 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 59 of 65 the investigational device in accordance with the Protocol. You will not receive any 
compensation for this injury. This agreement to  provide free medical tr eatment does not include 
treatment for any illness you might experience during the co urse of this study if  the illness is not 
the result of direct participation in the research study. 
PERSONS TO CONTACT FOR RESEARCH QUESTIONS 
If you have any questions about the research or experience an adverse reaction (any unusual 
symptoms) or injury, and if emergency medical treatment is required, you should immediately contact your study doctor, Dr. __________ at _____________.     If you have questions about your rights as a resear ch participant at this institution, you may call 
the Institutional Review Board at ________<insert contact information for IRB>.  
STUDY PARTICIPANT’S BILL OF RIGHTS 
Persons who participate in a medical experiment are entitled to certain rights.  These rights 
include but are not limited to the subject's right to: 
 Be informed of the nature a nd purpose of th e experiment; 
 Be given an explanation of th e procedures to be followed in the medical experiment, and 
any drug or device to be utilized; 
 Be given a description of any attendant discomforts and risks reasonably to be expected; 
 Be given an explanation of any benefits to the subject reasonably to be expected, if 
applicable; 
 Be given a disclosure of any appropriate alternatives, drugs,  or devices that might be 
advantageous to the subject, th eir relative risks, and benefits; 
 Be informed of the avenues of medical treatmen t, if any, available to the subject after the 
investigational procedure if complications should arise; 
 Be given an opportunity to as k questions concerning the expe riment or the procedures 
involved; 
 Be instructed that consent to participate in  the medical experiment may be withdrawn at 
any time and the subject may discontinue  participation wi thout prejudice; 
 Be given a copy of the signed and dated consent form; and 
 Be given the opportunity to decide to consent or not to consent to a medical experiment 
without the intervention of any element of for ce, fraud, deceit, duress,  coercion, or undue 
influence on the su bject's decision. 
CONSENT AND SIGNATURES 
PATIENT OR LEGALLY AUTH ORIZED REPRESENTATIVE 
I voluntarily consent to participate in this study.   The purpose and procedures of this study have 
been fully explained to me by the study investigator lis ted above.  All of my questions about the 
study have been satisfactor ily answered.  I am free to not participate in th is research study or to 
withdraw at any time, and that my current medical care will not be affected by this decision.  
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 60 of 65 I agree that my primary physician will be informed of  my participation in th is trial.  I authorize 
the release of my medical records to TriVascula r, agents of TriVascular, the Food and Drug 
Administration in the United Stat es, other governmental agencies, and the (Insert name of 
IRB/EC). 
 By signing and dating this consent form, I have not waived any of the legal rights that I would 
have if I were not a part icipant in a clinical  research study. I will rece ive and may keep a copy of 
this signed and dated consent form.  
 
 
________________________________________________________________ 
Participant’s (or representative) printed full name   ___________________________________  __ __ / __ __ / __ __ __ __ Participant’s (or representative) signature Date (dd/mm/yyyy) (written by the participant 
or his/her representative) 
 ________________________________________________________________ Impartial witness (full name) (Witness signature required  only in the event the patient cannot read and/or 
sign the Informed Consent; for instance, if the patient is illiterate or blind) 
 
_____________________________________  _______________________ Signature of the impartial witness (if required)   Date (dd/mm/yyyy) (written by the witness)  
 __________________________________  __ __ / __ __ / __ __ __ __ Principal Investigator or Author ized Designee  Date (dd/mm/yyyy) 
 
AUTHORIZATION OF USE AND DISCLOSURE 
PROTECTED HEALTH INFORMATION 
FOR RESEARCH PURPOSES 
(Sample HIPAA authorization) 
 
The privacy law, Health Insurance Portabilit y & Accountability Act (HIPAA), requires me to 
sign an agreement called an Authorization so th at the researchers can use or disclose my 
protected health informa tion for research purposes. 
I authorize Dr.  <insert name >   and his research staff, and the Sponsor of this study, 
TriVascular, Inc., to use and disclose my protected health info rmation for the purposes described 
below in the study titled, “A Pivotal Clinical St udy to Evaluate the Safety  and Effectiveness of 
the Ovation Abdominal Stent Graft System”.  I authorize the following individuals or groups to use or disclose my Protected Health Information: 
 <Insert Name of Hospital >; 
 My doctor(s) who care for me during this research.  These doctors include my primary 
care doctor and other doctors who may take care of me while I am part of this research. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 61 of 65  
The health information that may be used and disclosed includes: 
 All information collected during the research  described in the In formed Consent Form; 
and 
 Health information in my medical records that is relevant to the research described in the 
Informed Consent Form. 
The Researchers may: 
 Use and share my health inform ation to conduct the research; 
 Disclose my health information to the Sponsor  of the research, TriVascular, Inc. and its 
agents; 
 Disclose my health information as required by law; 
 Disclose my health informati on to representa tives of government or ganizations and other 
persons who are required to wa tch over the safety and effectiveness of medical products 
and therapies and the c onduct of research; and 
 Remove from my health information my name and other information that could be used to 
identify me. 
TriVascular, Inc. may: 
 Use and share my health inform ation to conduct the research; 
 Use my health information for additional purposes, such as other medical research, 
development of other study protocols, development of  new medical products or 
procedures, system analysis and other business pu rposes, except where prohibited by law; 
• Disclose my health inform ation as required by law; 
• Disclose my health information to represen tatives of government or ganizations and other 
persons who are required to watch over the sa fety and effectiveness of medical products 
and therapies, and the co nduct of research; and  
• Remove from my health information my name  and other information that could be used 
to identify me. 
 The Researchers may share my health information with: 
 <Insert Name of Instit utional Review Board>; 
 <Insert Name of Hospital Clinical Research Department>; 
 Government representatives,  when required by law; 
 <Insert any names of hospital representati ves, as applicable>; 
 TriVascular, Inc., as the Sponsor of the study, or its agents, such as data management 
groups, research monitoring groups, or  contract research organizations; 
 <Insert>  Other medical centers/instit utions/Investigators  outside of the name of hospital; 
 Your health insurer or payer, if necessary, in orde r to secure their pa yment for any covered 
treatment not paid fo r through the research. 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 62 of 65 Once my health information has been disclosed to a third party, federa l privacy laws may no 
longer protect it from fu rther disclosure.  The Researchers a nd TriVascular agree to protect my 
health information by using and disclosing it only as permitted by me in this Authorization and 
as directed by state and federal law.  Once informa tion that could be used to identify me has been 
removed, the information that remains is no longer  subject to this Authorization and may be used 
and disclosed by the Researchers and TriVascular as permitted by law.  No publication about the 
research will reveal my identity without my specific written permission.  I do not have to sign this Authorization.  If  I decide not to sign the Authorization: 
 It will not affect my treatment or my eligibility for health benefits. 
 I will not be able to  participate in the research study. 
 After signing the Authorization,  I can change my mind and: 
 Not let the Researcher disclose or use my  protected health in formation (revoke the 
Authorization), except fo r the information already collected for the study. 
 If I wish to revoke the Au thorization, I wi ll send a written letter to _________ <insert 
Name and address of Investigator>.  
 If I revoke the Authoriz ation, I can no longer pa rticipate in the study. 
Expiration: 
This Authorization expires at the conclusion of all work related to this  research study, which 
could be as long as six year s or until the study is comple ted, whichever is longer. 
 If I have not already received a copy of the No tice of Privacy Practices, I may request one.  If I 
have questions or concerns about my  privacy rights, I should contact <insert name and contact 
information for this person> . 
Authorization: 
I have read this information, and I will recei ve a copy of this form after it is signed. 
   
______________________________________  
Patient’s Printed Name 
 
 
______________________________________ ______________ Patient’s Signature Date 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 63 of 65 APPENDIX VI: CT SCANNING TECHNIQUES 
 
Reminders: 
• TriVascular requires contrast enhanced Spiral CT data for reconstruction. 
o Data must be uncompressed DICOM 
o Patient motion should be avoided during scan. If possible, avoid scanning non-
patient objects in field of view. Do not change patient position, table height, or field of view during scan. If patient moves,  repeat the study in its entirety.  
•
 Entire Exam sent to M2S via: Direct transfer of data via FTP or on optical disc sent via a 
traceable method. 
 Minimum Protocol 
(Required) High Resolution Protocol 
(Recommended) 
Scan Mode Helical  Helical  
Scan Parameters 110-140kVp, Auto mAs or 
170-400 mA scan time of 0.5sec 110-140kVp, Auto mAs or 
170-400 mA scan time of 0.5sec 
Slice Thickness  3mm 0.625 – 2mm 
Slice Interval  3mm 0.625 – 2mm 
Pitch 0.984:1 0.984:1 
Superior Extent AAA 2 cm above celiac artery origin 2 cm above celiac artery origin 
Inferior Extent AAA Pre-op: Lesser trochanter of femurs to 
include femoral bifurcations 
 
Post-op: At least 2cm distal to the 
lowest hypogastric artery origin Pre-op: Lesser trochanter of femurs to 
include femoral bifurcations 
 
Post-op: At least 2cm distal to the 
lowest hypogastric artery origin 
Contrast Standard per Radiology Department Standard per Radiology Department 
Volume 80ml contrast with 40ml saline flush 
or Standard Contrast Volume with 
Saline Flush per Radiology Department 80ml contrast with 40ml saline flush 
or Standard Contrast Volume with 
Saline Flush per Radiology Department 
Rate 4 ml/sec 4 ml/sec 
Scan Delay ROI – threshold 90-100 HU in aorta ROI – threshold 90-100 HU in aorta 
Field of View Large Body Large Body 
Reconstruction 
Algorithm Standard Standard 
 
 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 64 of 65 APPENDIX VII: EXPLANT PROCEDURE  
 
Explant During Surgical Conversion 
The objective of device removal is to minimize tr auma or damage to the device at the time of 
surgical excision from the subject, while maintaini ng the subject’s safety.  It is also important to 
minimize surrounding tissue disturbance so that a thorough pathological ev aluation can be made. 
1. If possible, a swab should be us ed to obtain material for microbi al culture prior to removal of 
the explant. 
2. Attempt to identify all components including their orientation so that th ey may be maintained 
in the same relative position as they were in situ . 
3. Attempt to remove the specimen en bloc from superior to the proximal sten t to inferior to the 
distal stent. 
4. The residual blood should be rinsed from the explant surfaces u tilizing physiological 
solutions such as Ringer’s lactate or normal sa line avoiding disturbance to the inside surface 
of the explant. 
5. All samples should be fixed in 10% neutral buffered formalin. 
6. Prior to the explant, please contact Tr iVascular to obtain sh ipping instructions. 
7. Please alert the sponsor within  24-hours of the explant and the shipment of the device. 
8. Explant case report forms shoul d be completed at this time 
9. An operative report and a separate  report from the examining pa thologist should be sent to 
the sponsor, if available. 
 
Explant During Autopsy 
The objective of device removal is to excise en bloc from superior to the proximal stent to 
inferior to the distal stent.  The abdominal aorta and iliacs should not be opened nor should any 
endovascular device manipulation be  done.  Photos should be taken in  anterior-posterior as well 
as oblique and lateral views.  The external ch aracteristics and the re lationship to surrounding 
viscera should be noted based on the guidelines on the case report forms.  Adhesions to viscera 
as well as evidence of fistula formation by erosion of the endograft thro ugh the arterial wall 
should be noted.  Any problems or abnormalities of this type should be photographed in situ , if 
possible. 1.
 If possible, a spiral CT scan with 3-D rec onstruction should be obtained of the endograft 
prior to explantation of the device.  Spiral CT  should be performed before immersion of the 
specimen in fixative. 
2. Attempt to identify all components including their orientation so that th ey may be maintained 
in the same relative position as they were in situ.  
3. Attempt to remove the specimen en bloc from superior to the proximal sten t to inferior to the 
distal stent. 
4. All samples should be fixed in 10% neutral buffered formalin. 
5. Prior to the explant, please contact Tr iVascular to obtain sh ipping instructions. 
6. Please alert the sponsor within  24-hours of the explant and the shipment of the device. 
7. An autopsy report and a separate report from th e examining pathologist should be sent to the 
sponsor, if available. 
 *These guidelines have been furnished by the Lifeline Registry of Endovascular Aneurysm 
Repair. 
TriVascular, Inc. Ovation™ Abdominal Stent Graft System  
 
Protocol #771-0006, Rev. J TriVascular Proprietary Information Page 65 of 65 Revision History 
Rev DCO #  Date  Description of Change Initiator 
A 2176 18Nov09 Initial Version of Document L. Mack 
B 2311 07Jan10 Revision of Juxtarenal aortic neck length from 7-
9 mm to <10 mm. L. Mack 
C 2350 21Jan10 Addition of Protocol Signature Page, Clinical 
Utility endpoint, and Revision of Statistical 
Section 10.0. L. Mack 
D 2412 10Feb10 Addition of Protoc ol Approval Page; deletion of 
references to “roll-in patients”; revisions to Imaging Core Lab and Schedule of Activities tables to be consistent with schedule of 
procedures discussed in body of protocol; 
clarification of visit timeframe allowances; correction of protocol title on screening informed consent and informed consent templates; specification of number of patients and exit visit procedure on informed consent template; and 
minor spelling corrections. L. Mack 
E 3238 13Aug10 Update verbiage based on DSMB’s request in 
response to UADE. M. Carr 
F 3551 20Oct10 Clarification of  allowable window for baseline 
procedures; incorporation of suggested investigator responsibilities as per “Guidance for 
Industry: Investigator Responsibilities” issued by the FDA in October of 2009. Update PI and product name. Added opt ional wound assessment 
at FU.  Removed ABI after Hospital Discharge. 
Made coagulation labs optional after Baseline. 
Requested site notification within 24 hours of device-related AEs. Modifications in response to FDA Conditional Approval letter dated 30 July 2010.  L. Mack 
G 3732 22Nov10 The Device Description and Patient Informed 
Consent were revised to include the use of iliac extensions. C. Campbell 
H 3759 23Nov10 Minor change to rename Section 1.0 of Protocol – 
Study Goal L. Mack 
I 3917 10Jan11 Revise to incorporate provisions for the continued 
access phase. C. Campbell 
J 4759 15Aug11 Revise number of additional subjects, modify 
follow-up periods, clarify sample size justification and remove DSMB wording added in previous revision. J German 
 